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ABSTRACT 
 
 This study investigates the role of branched-chain amino acid catabolism in rat myoblast 
differentiation. The branched-chain amino acids (BCAAs), particularly leucine, have been consistently 
shown to possess anabolic and anti-catabolic effects in regards to skeletal muscle hypertrophy and 
skeletal muscle differentiation. Metabolites of branched-chain amino acid catabolism have also been 
shown to induce similar effects, suggesting that production of these metabolites may mediate the effect of 
BCAA presence. However, the role of BCAA catabolism in skeletal muscle differentiation is not known. 
In skeletal muscle, the first step of BCAA catabolism is mediated by the branched-chain amino 
transferase-2 enzyme (BCAT2) to produce corresponding branched-chain keto acids (BCKAs). BCKAs 
can then be further catabolized by the mitochondrial branched-chain α-keto dehydrogenase complex 
(BCKD) to produce various acyl-CoA derivatives. Our research confirms that the leucine derived BCKA, 
α-ketoisocaproate (KIC), can positively regulate rat myoblast differentiation and ameliorate conditions of 
leucine deprivation. Furthermore, we demonstrate that disrupting the enzymes BCAT2 and BCKD that 
produce KIC and other BCAA metabolites results in impaired myoblast differentiation [MHC and 
troponin protein reduced by ~70-100%] and proliferation [cell viability reduced by ~15-25%]. Lastly, we 
show that myoblasts that have impaired BCAA catabolism have elevated levels of apoptosis [cleaved 
caspase-3 protein increased by ~100%]. Conclusively, our findings demonstrate that BCAA catabolism is 
an essential process that facilitates myoblast survival and differentiation. This research elucidates 
mechanisms which regulate skeletal muscle generation and recovery, and thus provides insight into novel 
targets that may promote muscle development in patients with myopathic diseases.  
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INTRODUCTION 
Skeletal muscle differentiation is a process by which precursor muscle cells called 
myoblasts mature and fuse with one another to form myotubes, which can also further develop to 
form skeletal muscle fibers. Skeletal muscle differentiation is an important process that enables 
the formation of new muscle tissue during embryo development or after muscle injury/damage 
[1]. This process has been found to be regulated by amino acid presence, especially the 
branched-chain amino acids (BCAAs) [2], which are a group of three amino acids that include 
leucine, isoleucine, and valine.  
Branched-chain amino acids are regarded as important anabolic stimulators of skeletal 
muscle hypertrophy and growth. In developed muscle, the BCAAs, and in particular leucine, can 
induce signaling that promotes protein synthesis via the mammalian/mechanistic target of 
rapamycin complex-1 (mTORC1) [3], [4], and inhibit mechanisms that mediate protein 
degradation via the ubiquitin-proteasome system [5] . In regards to muscle differentiation, the 
BCAA leucine has also been shown to be an essential regulator of the myogenic regulatory 
factors (MRFs) [6], and essential to adequate muscle satellite cell differentiation [7]. However, 
the mechanisms by which BCAAs exert their anabolic effects in regards to skeletal muscle 
differentiation have not been completely elucidated.  
There is evidence that suggests that BCAAs may exert their regulatory effects via 
metabolites produced from their catabolism. Previous literature has shown that the leucine 
metabolites α-ketoisocaproate (KIC) and β-hydroxy-β-methylbutyrate (HMB) can positively 
regulate skeletal muscle hypertrophy in animals and humans [8]–[13], while HMB has also been 
shown to positively regulate the differentiation of skeletal muscle myoblasts [14]. It has also 
been demonstrated that some of the anabolic effects observed with leucine supplementation are 
due to KIC production, rather than leucine itself [13].   
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The production of KIC, HMB, and other BCAA metabolites is mediated by the branched-
chain aminotransferase enzyme (BCAT) and branched-chain α-keto dehydrogenase complex 
(BCKD). BCAT reversibly transaminates BCAAs to produce corresponding branched-chain α-
keto acids (BCKAs). The BCKD complex mediates the rate-limiting irreversible step that 
decarboxylates BCKAs to produce corresponding acyl-CoA derivatives. Models of disrupted 
BCAT and BCKD activity in various animal and cell models result in compromises in skeletal 
muscle metabolism [15], [16], structure [17], function [18], [19], and endurance capacity [15]. 
Thus, there is evidence to believe that BCAA catabolism may play a critical role in the 
regulation of muscle differentiation by BCAAs, although this has not been investigated in 
previous studies. 
Accordingly, this study seeks to identify the importance of BCAA catabolism to the 
differentiation of skeletal muscle myoblasts. First, we seek to determine if BCAA metabolites 
other than HMB can also regulate skeletal muscle myoblast differentiation. More importantly, 
we attempt to determine what the effect of disrupting the BCAA catabolic enzymes, BCAT and 
BCKD, has on myoblast differentiation. This significance of this research is that it provides 
insight in to the mechanisms by which nutrition can affect muscle development. Although it is 
known branched-chain amino acids are important components of an adequate diet that facilitate 
the growth and maintenance of skeletal muscle, the mechanisms by which this is achieved are 
not completely known. Additionally, identifying the reasons by which BCAA catabolism 
facilitates adequate muscle development may lead to the identification of therapies that could 
treat patients with abnormal muscle metabolism and development resulting from impaired 
BCAA catabolism. 
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1.0 Skeletal Muscle 
 
1.1 Skeletal muscle structure and function 
 
 Skeletal muscle is the most abundant muscle tissue in the body, making up about 35% of 
the body’s total mass [20]. This organ is not only responsible for providing physical movement 
and support, but it is also involved in a plethora of metabolic reactions and maintenance of 
energy homeostasis. Skeletal muscle is a form of muscle tissue that is multi-nucleated, 
voluntarily activated, and striated. Its striated appearance is due to the presence of repeating 
functional units called sarcomeres. These sarcomeres contain an alternating pattern of dark and 
light bands that run along the length of muscle fibers, and it is the presence of the dark band 
which forms the distinct striations [21].  
Within the dark bands are complexes of overlapping ‘thick’ and ‘thin’ filaments. The 
interaction between thick and thin filaments are what give skeletal muscle its contractile 
properties. The thick filament is made from a protein known as myosin, and resembles ‘two 
hockey-sticks’ or ‘two golf-clubs’ twisted together. The two bulbous regions of the thick 
filament are referred to as the myosin heads. During a muscle contraction, the myosin heads bind 
to and pull themselves along the thin filament, which serves to shorten and contract sarcomeres, 
ultimately contracting the muscle fiber. This is referred to as the cross-bridge cycle. The thin 
filament is primarily made of actin, which is what the myosin heads form cross-bridges with. 
However, the thin filament also contains two proteins called troponin and tropomyosin. Under 
non-contractile conditions, tropomyosin blocks the binding site for myosin on actin and allows 
relaxation, or lengthening, of the muscle fiber. Conversely, when a muscle contraction is desired, 
calcium released in the muscle binds to troponin, which causes a conformational change in the 
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thin filament and moves tropomyosin out of the way of myosin. Thus, myosin can bind to actin 
and the cross-bridge cycle can occur. (Reviewed in [21]). 
It is also important to note that the term ‘muscle fiber’ is synonymous with ‘muscle cell’. 
A muscle cell is a bundle of individual smaller fibers that run the entire length of the muscle. 
These smaller fibers are called ‘myofibrils’, and the sarcomere functional units are contained 
within these smaller fibers. A muscle cell or fiber is surrounded by a plasma membrane, known 
as the sarcolemma, while the space between myofibrils is known as the sarcoplasm [21]. The 
reason muscle fibers are multi-nucleated is due to the way are formed, specifically, because they 
are formed via the fusion of several individual precursor muscle cells. This occurs as part of a 
process known as myogenesis [21]. 
1.2 Myogenesis 
Myogenesis refers to the formation of new muscle tissue, usually during embryonic 
development. In a nutshell, myogenesis involves myogenic progenitor cells committing to 
become myoblasts, which then proliferate and fuse to form muscle. These progenitor cells 
originate from the dorsal portion of somites, which are divisions of the embryo consisting of 
mesodermal tissue [22]. Progenitor cells delaminate from somites and migrate to the area where 
muscle will be developed. For example, limb muscle will originate from progenitor cells 
delaminated from limb-level somites. A number of genes control the migration of progenitor 
cells. Progenitor cells in Pax3 (-/-) mutant embryos (a gene that belongs to the paired-box (PAX) 
family of transcription factors) fail to migrate to the limb [23], and result in embryos that are 
missing appendicular, tongue, and diaphragm muscles, and greatly weakened body wall muscles 
[24]. The c-Met tyrosine receptor kinase is also expressed in migrating progenitor cells. Similar 
to Pax3 mutants, mice lacking c-Met do not form muscles of the limbs and diaphragm [25], and 
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muscle precursors fail to delaminate [26]. Lbx1 (ladybird-like homeobox-1) disruption has also 
been found to result in failure of progenitor migration to the limb [27].  Thus, these genes all 
serve critical functions in progenitor cell migration and the formation of muscle tissue.  
Once in the limb, the progenitor cells proliferate and become determined to form 
myoblasts [28].  This specialization of these precursor muscle cells is marked by an induction of 
the myogenic regulatory factors (MRFs), which are a family of basic helix-loop-helix (bHLH) 
transcription factors whose expression in a cell reflects their commitment to a myogenic fate 
[29]. The expression of the MRFs only occurs after the progenitor cells have migrated. The first 
MRFs to be expressed in embryonic myoblasts are MyoD and Myf5 [30], [31]. Before becoming 
programmed to differentiate, myoblasts proliferate, and both MyoD and Myf5 have been shown 
to be important to this process [32]–[34]. Sonic Hedgehog (SHH) is another protein that has been 
found to be implicated in myoblast proliferation, and responsible for activating MRF expression 
after migration [29], [35]. More recently, Brg1 (Brahma-related gene 1), a chromatin remodeling 
enzyme, was found to be required for mouse primary myoblast survival and proliferation. Brg1 
regulates cell proliferation and survival by inducing the transcription of Pax7, which is required 
for maintaining the viability of progenitor cells [36]. Lastly, the fibroblast growth factors FGF1 
and FGF2 can also regulate myoblast proliferation via interacting with cell surface receptors. 
These growth factors possess mitogenic activity, stimulating myoblast proliferation and 
preventing differentiation [37], [38] .  
1.2.1 Skeletal muscle differentiation 
Following the determination and proliferation of myoblasts, depending on environmental 
cues and internal signaling they can then differentiate and fuse into multi-nucleated myotubes. 
Myotubes further fuse with one another and mature to form muscle fibers. To enter 
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differentiation, myoblasts must first withdraw from the cell cycle during the G1 phase [39]. After 
committing to differentiation, myoblasts are unable to reenter the cell cycle. Cyclin dependent 
kinases (CDKs) are known to propagate the cell cycle, and p21, a CDK inhibitor has been found 
to be upregulated during muscle differentiation [40]. The retinoblastoma protein (pRb) is also a 
target of CDKs, and its inactivation is required for cell cycle progression. Inactivation occurs via 
phosphorylation by CDKs, and occurs during the G1 phase [41]. In its hypo-phosphorylated 
form, pRb disrupts G1/S transition by sequestering E2F transcription factors which are required 
for S phase entry [42]. Thus, it is no surprise that pRb is found to be hypo-phosphorylated in 
myotubes, which is believed to be in part responsible for permanent withdrawal from the cell 
cycle [43], [44].  
Based on these findings, regulation of the cell cycle is pivotal in determining whether or 
not myoblasts will differentiate. The myogenic regulatory factor MyoD has been shown to also 
regulate the cell cycle and thus is also important in the onset of differentiation. MyoD can 
directly upregulate p21 transcription in murine myoblasts as well as in non-myogenic cell lines 
[45]. Furthermore, MyoD can directly bind to pRb in its hypo-phosphorylated, active form [43]. 
This prevents pRb from becoming phosphorylated and thus inactivated, which would promote 
cell-cycle re-entry. On the other hand, MyoD function can actually be suppressed by the 
presence of growth factors, ultimately down-regulating myogenic activity [46]. MyoD 
expression is thus likely involved in cross-talk between cell-cycle signaling pathways, and is a 
key modulator in determining whether or not myoblasts enter differentiation.  
Another myogenic regulatory factor involved in myoblast differentiation is myogenin 
(Myf4). Myogenin has been found to be upregulated in mono-nucleated myoblasts in the post-
mitotic state (p21 positive) [47] , [48]. Upregulation of myogenin then initiates the expression of 
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muscle-specific structural proteins [48] and cell-to-cell fusion [48]–[50]. Mice that were 
generated with a homozygous mutation in the myogenin gene survived fetal development, but 
were postnatally immobile and died soon after birth [51]. These mice also show a severe 
reduction in skeletal muscle. The essentiality of myogenin in fetal muscle development has also 
been reported elsewhere [52], and is most important during later stages of myogenesis [53]. 
Interestingly, in cultured mouse myoblasts it was found that down-regulating myogenin actually 
caused a reversal of terminal differentiation in differentiated myotubes [54]. siRNA mediated 
knockdown of myogenin caused cellular cleavage of myotubes back into mono-nucleated cells, 
and induced cell-cycle re-entry. Furthermore, expressing MyoD simultaneously with myogenin 
knockdown was not able to prevent this phenomenon, indicating that myogenin itself is crucial in 
maintaining terminal differentiation [54].  Conclusively, myogenin is a transcription factor that is 
required for the terminal differentiation and fusion of myoblasts into mature and functional 
muscle tissue.  
1.2.2 Myogenesis via satellite cells 
Existing muscle tissue also contains a capacity to regenerate and form new muscle fibers, 
usually in response to muscle damage. In late fetal development, progenitor cells populate 
muscle in satellite positions around myofibers and are marked by the expression of Pax7. These 
‘satellite cells’ possess an ability to exit quiescence and become myogenic under conditions of 
stress or trauma. Upon their activation, satellite cells proliferate and differentiate into myoblasts, 
which can also further proliferate and differentiate to form new muscle fibers. The process has 
also been found to be regulated by several factors including the MRFs (MyoD, Myf5, myogenin, 
MRF4), Pax3, and Pax7. (Reviewed in [1]) 
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2.0 Signaling pathways that regulate skeletal muscle differentiation 
The myogenic regulatory factors that induce skeletal muscle differentiation are regulated 
by many upstream signaling pathways. Based on cues such as energy availability, nutritional 
status, and ligand binding, these signals can be either inhibitor or stimulatory on the 
transcriptional and post-transcriptional regulation of the MRFs. The onset and progression of 
skeletal muscle differentiation has been shown to be extensively regulated by peptide growth 
factors such as insulin-like growth factor (IGF), fibroblast growth factor (FGF), and transforming 
growth factor β (TGF-β). IGF and FGF signaling has been shown to have a stimulatory effect on 
myoblast differentiation [55]–[57], while conversely TGF-β has a repressive effect [58], [59]. 
Myostatin, a member of the TGF-β family of growth factors, has been well characterized as a 
negative regulator of skeletal muscle anabolism [60], [61], and has been observed to also 
interfere with myoblast proliferation and differentiation [62], [63]. The presence of myostatin in 
culture medium causes a down regulation of MyoD, Myf5, myogenin, and p21, while subsequent 
removal of myostatin allows differentiation to progress and a recovery of these markers [63].  
2.1 TGF-β/SMAD signaling in skeletal muscle differentiation 
Myostatin is believed to signal through the canonical TGF-β signaling pathway, which 
begins with myostatin binding to the activin type II receptors [64]. This is followed by the 
translocation of the type II receptor to the corresponding type I receptor forming a receptor 
complex [64]. This activated complex then phosphorylates the SMAD2 and SMAD3 proteins 
[65]. The SMAD family of proteins are intracellular mediators of TGF-β signaling which can 
modulate gene transcription. After being phosphorylated, SMAD2 and SMAD3 form a hetero-
multimeric complex with SMAD4, which is then able to translocate to the nucleus. Upon entry 
into the nucleus, this complex binds directly to or in complex with components of DNA that 
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either stimulate or inhibit the transcription of specific target genes. In regards to skeletal muscle 
differentiation, there is evidence to believe that select SMAD proteins mediate the inhibitory 
effect of TGF-β signaling on myoblast differentiation. siRNA knockdown of SMAD2/3 in mouse 
myoblasts caused a 100% increase in myogenin expression, as well as an increase in myosin 
expression during differentiation [66]. Another study also found that myostatin-induced 
phosphorylation of SMAD3 causes an inhibitory binding with MyoD protein [63]. Additionally, 
the expression of a dominant-negative construct of SMAD3 was able to rescue luciferase activity 
of the MyoD promoter-reporter, which was otherwise inhibited by myostatin [63].  Thus, the 
SMAD proteins can negatively regulate skeletal muscle differentiation in response to TGF-β 
signaling.  
2.2 Notch signaling  
Another pathway which plays an important role in the regulation of embryonic and post-
natal skeletal muscle differentiation is the Notch signaling pathway. Notch signaling is believed 
to be inhibitory on skeletal muscle differentiation. It has been shown that Notch can localize to 
the nucleus in mouse myoblasts, and bind to the bHLH domain of MyoD, hindering its effects on 
regulating transcription of myogenic genes [67], [68]. This mechanism can serve to prevent 
premature myoblast commitment to differentiation.  The Notch inhibitor, Numb, is also 
expressed in myogenic cell lines [69]. It has been found that Numb expression leads to the 
commitment of progenitor cells to the myoblast cell fate, as well as expression of myogenic 
regulatory factors such as Myf5 and myogenin [68], [70]. On the contrary, Numb negative cells 
depict an opposing expression profile with higher levels of the pre-myoblast marker Pax3 [70]. 
Thus, down-regulation of Notch via Numb is required for myoblast differentiation.  
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Notch signaling can also act as a mediator in sensing environmental status. Reduced 
oxygen availability, or hypoxia, has been shown to influence the proliferation and differentiation 
of progenitor cells in various cell lines. Nervous tissue and adipocyte progenitor cells cultured 
under hypoxic conditions both show increased proliferation and a preference to maintain an 
undifferentiated state [71]–[73]. In regards to skeletal muscle differentiation, one study found 
that culturing mouse myoblasts in 1% O2 for four days resulted in a four-fold decrease in the 
number of differentiated cells [74]. This study also concluded the effects of hypoxia on myoblast 
differentiation occur through Notch signaling. As they observed, adding an inhibitor of Notch 
cleavage in combination with exposure to hypoxia resulted in a significant attenuation of 
hypoxia-induced inhibition of differentiation. Notch signaling has also been shown to be 
implicated in hypoxia-induced effects on proliferation and differentiation in other cell lines [75]–
[77].  
  2.3 MAPK signaling 
Extracellular signaling via insulin and insulin-like growth factors have also been found to 
regulate differentiation through MAPK signaling. The mitogen-activated protein kinases 
(MAPKs) are a family of proteins that include ERK (extracellular signal-regulated kinase), JNK 
(jun N-terminal kinase), and p38. These protein kinases are activated in response to growth 
factor presence, with evidence suggesting that the activation of p38 and ERK are more important 
in differentiating myoblasts. Cultured rat myoblasts that have dysfunctional p38 regulation 
express an inability to differentiate [78], [79]. Furthermore, abolishing p38 activation also 
disrupts the phosphorylation and activation of myocyte enhancement factor-2A (MEF2a) [80]. 
MEF2a is a transcription factor that is able to translocate to the nucleus and positively regulate 
the expression of myogenic genes [81], as well as form protein-protein interactions with bHLH 
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transcription factors MyoD and myogenin that increases their functional activity [82]. A binding 
site for MEF2 within the myogenin promoter region has also been found in cultured mouse 
myoblasts and embryos, and has been shown to be essential for myogenin transcription [83], 
[84]. Similarly, transcription of the MyoD gene in Xenopus (XMyoDa) is regulated by a MEF2 
site that overlaps with the TATA box [85].  
MyoD also cannot bind to DNA and regulate transcription without first hetero-dimerizing 
with E proteins that bind to E-boxes on promoters. E proteins allow binding of transcription 
factors to DNA elements. Activation of p38 is believed to increase the affinity of MyoD with 
E47 protein which results in an increase in muscle-specific gene transcription [86].  
 In addition to p38, ERK1/2 is another MAPK that has regulatory functions in not only in 
the differentiation of myoblasts, but in their proliferation as well. Growth factors such as IGF-1 
and FGF can signal through ERK to maintain myoblast proliferation by preventing cell cycle exit 
and promoting entry into the S phase [87]–[89]. However, once the cells reach confluency IGF-1 
stimulates differentiation, although this is believed to occur through the PI3K/Akt pathway [90]. 
On the other hand, FGF signaling through ERK continues to promote proliferation and prevent 
differentiation. It is believed this is achieved by preventing nuclear localization and function of 
MEF2a [91], as well as inhibiting the transcription of MyoD [92], [93]. Thus, it is no surprise 
that during skeletal muscle differentiation FGF receptors are lost and ERK activity is diminished 
[94], [95]. 
2.4 Akt  
Insulin and insulin-like growth factors also can induce Akt signaling within skeletal 
muscle myoblasts. Akt plays a significant role in growth factor and insulin signaling, and has 
been found to regulate the phosphorylation of downstream targets that regulate skeletal muscle 
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differentiation. The Akt pathway is activated by the binding of either insulin to the insulin 
receptor, or IGF to the IGF receptor. These receptors, being tyrosine kinases, are then able to 
phosphorylate the insulin-receptor substrates (IRS).  Activated IRS then recruits and 
phosphorylates the lipid kinase phosphatidylinositol 3-kinase (PI3K). Phosphorylated PI3K then 
produces the membrane-bound PI(3,4)P2 and PI(3,4,5)P3 from PI(4)P and PI(4,5)P2, respectively. 
The significance of this phosphorylation is that it causes a co-localization of phosphoinositide-
dependent kinase-1/2 (PDK1/2) with Akt at the plasma membrane. PDK1 and mTORC2 then 
phosphorylate Akt at two separate sites, Thr308 and Ser473, respectively, which leads to its 
activation. (reviewed in [90], [96]). 
The phosphorylation and activation of Akt allows it to phosphorylate further downstream 
targets. One such target is glycogen synthase kinase-3β (GSK-3β), which becomes inactivated 
upon phosphorylation. GSK-3β is believed to have an inhibitory role in skeletal muscle 
differentiation, in part by antagonizing the activation of MEF2 via p38-MAPK [97]. Suppression 
of GSK-3β allows the nuclear localization and accumulation of β-catenin and NFATC3, which 
are genes that have been shown to also upregulate the transcription of myogenic genes [98]–
[100]. In myoblasts, the activities of MEF2 and MyoD are also suppressed in part by being 
bound to the transcriptional repressor prohibitin-2 protein (PHB2). An isoform of Akt, Akt2, is 
able to mitigate this suppression by binding to and downregulating PHB2 [101]. Akt-mediated 
inhibitory phosphorylation of the FoxO family of transcription factors also facilitates the onset of 
differentiation [102]. It has been shown that activation of the forkhead box O (FoxO) 
transcription factors can attenuate expression of MyoD, and that this preclusion is mediated by 
an increase in Notch signaling [103]. Lastly, Akt2 can bind to p21, and prevent it from becoming 
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inhibited via phosphorylation [104]. Recall that p21, a cyclin-dependent kinase inhibitor, 
promotes cell cycle exit and differentiation.  
2.5 mTOR  
The mammalian/mechanistic target of rapamycin (mTOR) is a serine/threonine kinase 
that integrates both intracellular and extracellular signals which regulate skeletal muscle 
differentiation.  In the 1990s, it was discovered that the molecule rapamycin caused toxic and 
anti-proliferative effects in budding yeast [105]. The proteins TOR1 and TOR2 (target of 
rapamycin 1 & 2) were found to be mediators of this effect [106], [107]. Further research in 
mammalian cell lines lead to the discovery and isolation of mTOR, which was homologous to 
the yeast TORs [108]. 
mTOR belongs to the phosphoinositide 3-kinase (PI3K)-related kinase family, and forms 
two distinct complexes, mTORC1 and mTORC2. These complexes differ in their subunits, 
upstream/downstream signaling, and sensitivity to rapamycin. In addition to mTOR, mTORC1 is 
comprised of the following proteins: regulatory associated protein of mTOR (RAPTOR), 
mammalian lethal with SEC13 protein 8 (MLST8), proline-rich AKT substrate of 40 kDa 
(PRAS40), DEP domain-containing mTOR-interacting protein (DEPTOR), and the Tti1/Tel2 
complex of scaffold proteins. On the other hand, mTORC2 is comprised of mTOR, MLST8, 
DEPTOR, Tti1/Tel2 along with the rapamycin-insensitive companion of mTOR (RICTOR), 
mammalian stress-activated map kinase-interacting protein 1 (mSin1), and protein observed with 
Rictor 1/2 (Protor1/2)  (reviewed in [109]). The RAPTOR protein is what mediates mTORC1 
vulnerability to rapamycin, as rapamycin can form a complex with 12-kDa FK506-binding 
protein (FKBP12) that directly binds to RAPTOR and inhibits mTORC1 activity [108]. 
Conversely, mTORC2 does not have the RAPTOR protein, but instead a rapamycin-insensitive 
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RICTOR protein. Thus, mTORC2 is much less sensitive to rapamycin treatment, although 
prolonged exposure to rapamycin in certain cell types can induce inhibition of mTORC2 [110].  
An abundance of research has focused on the role of mTORC1, as it has been found to be 
an indispensable mediator of numerous processes in the cell. mTORC1 is important in regulating 
autophagy, lipid synthesis, cell cycle progression, and protein synthesis, in response to 
nutrient/energy availability and growth factor presence (reviewed in [89], [94]). In regards to 
skeletal muscle growth and hypertrophy, mTORC1 is believed to integrate the effect of 
extracellular signals such as growth factors and amino acids, to anabolic mechanisms within the 
cell. In existing muscle, one of the well characterized effects of mTORC1 activity in response to 
extracellular anabolic stimuli is increased protein synthesis. This is achieved via the kinase 
activity of mTORC1, which phosphorylates its downstream targets p70 S6 kinase-1 (S6K1) and 
eIF4E-binding protein-1 (4E-BP1). The phosphorylation of 4E-BP1 prevents it from inhibitory 
binding to eIF4E, which enables eIF4E to promote cap-dependent translation. The 
phosphorylation of S6K1 stimulates mRNA synthesis, cap-dependent translation and elongation, 
and the synthesis of ribosomal proteins, via the phosphorylation of further downstream targets 
such as ribosomal protein S6 (rpS6), among others (reviewed in [111]). The role of mTORC2 in 
skeletal muscle hypertrophy and growth is less clear, although it has been found that mTORC2 is 
a regulator of actin cytoskeleton reorganization along with cell survival and proliferation [112].  
In regards to skeletal muscle differentiation, it has been concretely shown that rapamycin 
treatment can affect differentiation. Experiments have shown that rapamycin treatment can 
inhibit differentiation in rat and mouse myoblast lines [113], [114].  Rapamycin has also been 
shown to abrogate skeletal muscle regeneration in mice [113]. Furthermore, when rapamycin 
was administered to myoblasts with mutant rapamycin-resistant (RR) mTOR, differentiation was 
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restored [114]. This supports the idea that rapamycin-sensitive mTOR has important functions in 
skeletal muscle differentiation. It is not entirely clear how mTOR positively regulates 
differentiation; however, so far it has been found that both kinase-dependent and kinase-
independent mechanisms work to regulate this process. The kinase-independent activity of 
mTOR is believed to promote IGF-II transcription during differentiation [115]. IGF-II is then 
secreted by muscle cells and acts as an extracellular signal that activates the IRS/PI3K/AKT 
pathways, which promotes differentiation [116]. The kinase-dependent function of mTOR has 
been observed to be critically important in later stages of differentiation involving myoblast 
fusion and maturation [117]. Further research has shown that this importance is in part due to the 
fact that mTOR can positively regulate the expression of follistatin [118], a myocyte-secreted 
factor that antagonizes the effects of myostatin and other TGFβ related cytokines that suppress 
differentiation [119], [120].  
The fact that myoblast differentiation is rapamycin sensitive, suggests that the mTOR-
containing complex mTORC1 is likely a key positive regulator of muscle differentiation. 
However, studies that examine mTORC1 function in muscle differentiation do not paint a clear 
picture that supports this notion.  Knocking out RAPTOR, a component of mTORC1, results in 
enhanced differentiation of C2C12 mouse myoblasts, while overexpression of RAPTOR results 
in the inhibition of their differentiation [121]. It was shown that this phenomenon is a result of 
RAPTOR affecting mTORC1 phosphorylation of IRS-1 on its Serine-307 residue. IRS-1 activity 
is a key step in insulin and growth factor induced IRS/PI3K/AKT signaling, and phosphorylation 
on this residue results in IRS-1 destabilization and disruption of this pathway [122]. It was 
observed that knocking out RAPTOR and disrupting mTORC1 function prevented this inhibitory 
phosphorylation of IRS-1, facilitating myoblast differentiation through adequate AKT signaling. 
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Conversely, overexpressing RAPTOR, thus increasing mTORC1 function, promotes 
destabilizing phosphorylation of IRS-1 and disrupts AKT-mediated myoblast differentiation.  In 
another study, the well characterized target of mTORC1, S6K1, which has been concretely 
shown to stimulate skeletal muscle hypertrophy, was also found to be dispensable for the 
adequate differentiation of mouse myoblasts [123]. Thus, it is apparent that mechanisms 
involving mTORC1 are not consistent across models of skeletal muscle growth and hypertrophy 
compared to those involving muscle differentiation, as mTORC1 has been found to have a 
positive role in the former but a dispensable/negative role in the latter. Lastly, the fact that 
skeletal muscle differentiation was rapamycin sensitive, but not mTORC1 dependent, suggests 
that other rapamycin-sensitive mTOR complexes (such as mTORC2) regulate muscle 
differentiation. Accordingly, mTORC2 has been found to positively regulate the terminal 
differentiation of mouse myoblasts [124]. 
 
3.0 Amino acid induced regulation of skeletal muscle anabolism 
The mechanisms by which signaling pathways in muscle development are regulated are in 
large part due to a response to upstream stimuli. These stimuli are mostly nutrient/environmental 
cues, such as amino acid availability. It has been well established that amino acids serve as the 
building blocks of peptide-chains which form muscle proteins. However, in addition to this 
canonical role, it has also been observed that amino acids can act as signaling molecules that 
drive anabolic signaling mechanisms in skeletal muscle. 
3.1 Amino acid signaling in skeletal muscle hypertrophy 
In existing muscle, amino acids have most notably been shown to stimulate the activity of 
mTORC1, which promotes the transcription and translation of myogenic proteins, while also 
 19 
suppressing proteolytic mechanisms such as autophagy (reviewed in [125]). The upstream 
signals which connect mTORC1 responsiveness to amino acid presence have also been well 
studied in existing muscle. These include the small GTPase Rag heterodimers, and the class III 
PI3K protein Vps34.  Upon being activated by the guanine nucleotide exchange factor activity of 
the Ragulator protein complex, the Rag heterodimers bind to RAPTOR and recruit mTORC1 to 
the lysosomal surface in response to amino acid presence [126]–[128]. The translocation of 
mTORC1 to the lysosomal membrane is required for its activation [129]. Vps34 mediates amino 
acid induced activation of mTORC1 by facilitating the translocation of phospholipase D1 
(PLD1) also to the lysosomal region, where its product phosphatidic acid (PA) can activate 
mTORC1 by displacing the inhibitory subunit DEPTOR [130], [131]. The activation of 
mTORC1 can then drive skeletal muscle growth and hypertrophy in response to amino acids.  
 3.2 Amino acid signaling in skeletal muscle differentiation 
Although pathways connecting amino acid presence to anabolic mechanisms have been 
elucidated in existing muscle, such mechanisms have not been as well studied during 
myogenesis. There is little that is known about how amino acid presence signals to promote 
anabolic mechanisms during myoblast differentiation. As previously mentioned, the Rag and 
Vps34 pathways have been shown to act as the amino acid-sensing molecules in existing muscle, 
which promote growth via mTORC1. However, because mTORC1 is believed to have 
differential roles when comparing skeletal muscle hypertrophy to skeletal muscle differentiation, 
the aforementioned model of amino acid sensing might not apply to differentiation. Yoon & 
Chen (2013) [2] were the first to elucidate the role of mTOR and mTORC1 and its upstream 
signaling in response to amino acids, in the context of differentiating mouse myoblasts. 
Interestingly, although they found the levels of the Rags to increase during differentiation, they 
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concluded the Rags to be negative regulators of myoblast differentiation, as introducing shRNA 
for RagA and RagB resulted in significantly better myoblast fusion and myogenic protein 
expression. They found that this was because the Rags were necessary for amino acid induced 
activation of mTORC1. In congruence with previous literature, they found that activation of 
mTORC1 during differentiation and in response to amino acids caused destabilizing 
phosphorylation of IRS-1, ultimately disrupting AKT signaling. This result demonstrated that 
amino-acid-induced activation of the Rags can promote negative signaling in muscle 
differentiation. Yoon & Chen (2013) [2] then turned to the Vps34 signaling pathway in an 
attempt to identify its role in regulating differentiation in response to amino acids. In two 
separate experiments where Vps34 was disrupted either by using a PI3K inhibitor or by shRNA, 
it was found that disrupting Vps34 significantly attenuated myoblast differentiation, suggesting 
Vps34 activity has a positive role on differentiation. In response to amino acids, they found the 
activity of PLD (target of Vps34) to increase, which ultimately promoted IGF-II transcription. 
Introducing Torin1 (an inhibitor of mTORC1/mTORC2) did not affect IGF-11 expression; 
whereas, using rapamycin abrogated IGF-11 expression, suggesting that a rapamycin-sensitive 
mTOR complex other than mTORC1/2 mediates the anabolic signaling effects of amino acids. 
The results of this study demonstrated that 1) amino acid presence induces both positive and 
negative signaling in regards to muscle differentiation, although the positive signaling likely 
outweighs negative signaling as amino acid presence overall stimulates differentiation 2) the Rag 
proteins have opposite roles in amino acid sensing when looking at models of skeletal muscle 
hypertrophy and muscle differentiation 3) Vps34 has a similar positive role in amino acid 
sensing when comparing muscle hypertrophy and differentiation. This study also provided 
further evidence to the argument that mTORC1 can act as a negative regulator of myoblast 
 21 
differentiation, whereas mTOR or another mTOR containing complex is a key positive regulator. 
However, it was odd that disrupting mTORC2 with Torin1 did not affect IGF-11, as mTORC2 
has been shown to positively regulate differentiation [124]. Nonetheless, the mechanisms by 
which amino acids induce and regulate skeletal muscle differentiation are still far from being 
clearly understood, and there likely exists other unknown mechanisms that coordinate this 
phenomenon.  
 
4.0 Branched-chain amino acids 
 As discussed in previous sections, amino acids can induce signaling pathways that 
promote skeletal muscle hypertrophy and muscle differentiation. However, the role and potency 
of individual amino acids in this model is another question that remains to be completely 
understood. Evidence to date suggests that the presence of certain amino acids can promote 
muscle anabolism to a greater extent than others. The most notable amino acids which exhibit 
such effects are the branched-chain amino acids: leucine, isoleucine, and valine. The branched-
chain amino acids (BCAAs) are essential amino acids characterized by having a branched 
aliphatic side chain from the central carbon atom (Figure 1). In humans, the BCAAs constitute 
~35% of the essential amino acids in muscle proteins and 14-18% of the total amino acids in 
muscle proteins [132]. 
  
 
 
 
 
Figure 1: Chemical structure of the three branched-chain amino acids (BCAAs): valine, leucine, 
and leucine. Image source: University of Illinois [218]. 
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4.1 BCAAs and skeletal muscle hypertrophy 
Numerous studies have focused on the effects of the branched-chain amino acids on 
existing skeletal muscle. BCAA supplementation has been shown to promote skeletal muscle 
protein synthesis [133]–[136], reduce proteolysis [133], [137]–[139], enhance muscle recovery 
[137], [140], [141], and increase muscle endurance [142], [143]. Because of their ability to 
promote muscle growth and maintenance and prevent muscle loss, even under conditions of 
nutrient deprivation, BCAAs are also considered to be anti-sarcopenic, anti-cachectic, and anti-
anorectic agents [144]–[146].  Of the three BCAAs, leucine is believed to be a more potent 
amino acid in mediating the stimulation of protein synthesis in skeletal muscle. In vitro studies 
show that incubating diaphragm or gastrocnemius muscle with leucine alone is nearly as 
effective in stimulating protein synthesis as all three BCAAs [133], [147]. Another study in vivo 
showed that oral administration of isoleucine and valine did not significantly stimulate protein 
synthesis in fasted rats, whereas leucine did [148]. However, another study demonstrated that 
intravenous leucine administration does not stimulate protein synthesis in gastrocnemius or heart 
muscle of fasted rats [149]. Thus, although the method of administration can affect leucine 
stimulation of protein synthesis in vivo, leucine has been shown to promote protein synthesis 
without the presence of the other two BCAAs. Nonetheless, the presence of isoleucine and valine 
are still important in mediating some of the other beneficial effects observed with BCAA 
administration [150].  
 4.1.1 Mechanisms mediating BCAA effects in existing muscle 
The signaling mechanisms that sense BCAA presence and coordinate responses in 
muscle have been well studied. In existing skeletal muscle, it is believed the BCAAs can regulate 
skeletal muscle anabolism in part through mTORC1. In regards to protein synthesis, leucine 
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supplementation has been shown to increase the phosphorylation of p70-S6K1, 4E-BP1, and S6 
in muscle [151]–[153]. As previously described, these proteins are targets of the mTORC1 
kinase and result in increased levels of protein synthesis. Thus, leucine can affect mTORC1 
signaling to increase levels of protein synthesis [4], [154], [155]. The presence of insulin is also 
believed to regulate the stimulatory action of leucine on mTORC1. Administration of the insulin 
inhibitor somatostatin to rats supplemented with leucine resulted in an attenuation of leucine-
induced increases in 4E-BP1 and S6K1 phosphorylation, depicting an insulin dependent 
mechanism via mTORC1. However, leucine-induced assembly of eIF4E and eIF4G was not 
affected by somatostatin, thus indicating an insulin-independent mechanism for this process.  
The mechanism by which leucine causes mTORC1 activation is also becoming 
increasingly more clear. It has been found that leucine can directly bind to Sestrin-2, a GATOR2 
interacting protein that inhibits mTORC1 signaling.  The binding of leucine to Sestrin-2 prevents 
inhibitory binding of Sestrin-2 to GATOR2. This allows the GATOR2 complex to inhibit the 
action of the GTPase activating protein GATOR1 [156], which would normally inhibit the 
RagA/B proteins from becoming GTP loaded. Via the action of the v-ATPase and Ragulator 
guanine exchange factor, RagA/B become GTP loaded under amino acid presence and recruit 
mTORC1 to the lysosomal surface where it can be activated [3], [129].  
 BCAA supplementation has also been shown to attenuate atrophy in skeletal muscle. 
When rats were subjected to a hind-limb suspension protocol to model disuse atrophy, 
supplementing the rats with an oral BCAA mixture (600mg/(kg day)) significantly reduced the 
loss in muscle weight and cross-sectional area of the muscle fibers [157]. Furthermore, the rats 
supplemented with BCAAs had attenuated levels of atrogin-1 and MuRF1 proteins, which are 
classified as E3 ubiquitin ligases that are important in regulating protein degradation via the 
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ubiquitin-proteasome system. Another study showed that supplementing individuals with 
BCAAs reduced levels of atrogin-1 in resting vastus lateralis (VL) muscle, and MuRF1 in both 
rested and exercised VL muscle [158].  Thus, these results indicate that BCAA supplementation 
can mitigate losses in muscle protein by down-regulating components of the ubiquitin-
proteasome system. The mechanism by which BCAAs regulate the expression of atrogin-1 and 
MuRF1 is not completely clear. It has been shown that the attenuation of atrogin-1 via leucine 
occurs in an mTOR dependent manner in C2C12 mouse myoblasts [5]. On the other hand, the 
mechanism that causes the attenuation of MuRF1 in response to BCAA is not known. 
Nonetheless, the fact that BCAAs can downregulate atrogin-1 and MuRF1 partially explain why 
BCAAs can prevent muscle damage and promote faster muscle recovery [159], [160].  
 The beneficial effect of BCAA supplementation on muscle endurance has also been 
established. Supplementing individuals with a 0.4% BCAA drink in combination with 4% 
carbohydrates was shown to increase maximal VO2 capacity and lactate threshold levels 
following endurance exercise [161]. Other studies have also shown that BCAA supplementation 
can increase time to fatigue, lower perceived exertion, lower the respiratory exchange ratio 
(RER), and increase plasma glucose during exercise [142], [162]–[164]. These effects resulting 
from BCAA supplementation may be in part explained by the fact that BCAAs can increase 
mitochondrial biogenesis in skeletal muscle. D’Antona et al. 2010 [165] showed that 
administering a BCAA mixture to adult cardiac myocytes in-vitro resulted in a dose-dependent 
increase in mitochondrial biogenesis, as indicated by increases in mtDNA and transcription of 
mitochondrial biogenic genes PGC-1α, NRF-1, and the β subunit of the mitochondrial H+-ATP 
synthase. In-vivo experiments by the same group yielded similar results as they observed 
increases in mitochondrial biogenesis and expression of mitochondrial regulatory genes in heart, 
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diaphragm, soleus, and tibialis muscles following a 3-month supplementation protocol. 
Additionally, they found that the increases in mitochondrial content were nearly twice as great in 
mice that were treated with BCAA supplementation and simultaneous endurance exercise. 
Increased oxidative damage due to reactive oxygen species (ROS) accumulation is a key factor 
in muscle damage and aging. Compared to untreated mice, they also found that BCAA 
supplemented mice showed reduced mitochondrial ROS production, as well as an increased 
capacity to eliminate superoxides in the mitochondria. Conclusively, increased endurance 
capacity seen with BCAA supplementation likely results from an increase in mitochondrial 
content in muscle tissues. The increase in ROS elimination may also contribute to enhanced 
mitochondrial function and the attenuation of muscle damage.  
4.2 BCAAs and skeletal muscle differentiation 
 Although the beneficial and anabolic effects of BCAAs have been well established in 
existing muscles tissue, the effects of BCAAs on muscle myogenesis are less known. More 
specifically, the question of whether BCAAs play a significant role in regulating the skeletal 
muscle differentiation program is not clear. Averous et al. 2012 [6] attempted to elucidate the 
effect that leucine withdrawal has on mouse myoblasts that were subjected to a differentiation 
protocol. They observed that removing leucine from the differentiation media completely 
prevented the myoblasts from differentiating and caused cell cycle arrest.  Additionally, when 
they examined the regulation of the myogenic regulatory factors (MRFs), they observed that the 
regulation of Myf5 and MyoD was modified as a result of leucine deprivation. Under control 
conditions, they found Myf5 protein to increase in expression up to 4h of differentiation, then 
decrease in expression at 8h and all subsequent time points to day 5. In the absence of leucine, 
they found that Myf5 expression was similarly increased at 4h, however at 8h and onward they 
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found its levels to be significantly increased compared to control. Regarding MyoD, in control 
conditions its protein level remained constant to day 3 of differentiation then decreased upon 
reaching terminal differentiation. In leucine-deprived cells they observed MyoD protein to be 
significantly lower at 8h and on to day 5 of differentiation. mRNA analysis showed that Myf5 
followed the same pattern as its protein expression in treatment and control conditions; however, 
MyoD mRNA expression was not modified by either control or leucine-deprived conditions. 
Their subsequent experiments in primary mouse satellite cells yielded similar observations in 
both MyoD and Myf5 protein expression under conditions of leucine presence and leucine 
deprivation. These results indicate that leucine presence is critical in regulating the normal 
expression pattern of the myogenic regulatory factors during muscle differentiation.  
 Dai et al. 2015 [7] examined the role of leucine in differentiating primary rat satellite 
cells. Their work demonstrated that leucine promoted satellite cell differentiation in a dose-
dependent manner. Cells cultured in medium containing 0.5 mM leucine resulted in myotubes 
that were thick, long, and showed rhythmic contraction. However, cells differentiated in medium 
that only contained 0.1 mM leucine resulted in myotubes that were shorter, thinner, and did not 
display rhythmic contractions.  Thus, these findings also support the notion that the branched-
chain amino acid leucine can positively regulate skeletal muscle differentiation. 
 Unfortunately these two studies are the only ones that have looked at the effects of 
BCAA alone on skeletal muscle differentiation. The effects of other BCAAs, valine and 
isoleucine, have not been examined in this manner to date. Clearly, further research is required to 
examine the full contribution of branched-chain amino acids to skeletal muscle differentiation.  
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4.2.1 Mechanisms mediating BCAA effects in skeletal muscle differentiation 
 The pathways mediating the effect of leucine on the skeletal muscle differentiation 
program were also examined in the aforementioned studies.  Averous et al. 2012 [6] 
demonstrated that although leucine presence was able to regulate mTORC1 activity in mouse 
myoblasts, neither mTORC1 nor any other rapamycin-sensitive mTOR complex was required for 
the increase in Myf5 and decrease in MyoD expression they observed as a result of leucine 
withdrawal. The finding that mTORC1 was not involved in nutrient-induced regulation of 
differentiation falls in line with previous research that mTORC1 is insignificant in the regulation 
of myoblast differentiation. However, their finding that another rapamycin-sensitive mTOR 
complex was also not involved in the regulation of MyoD and Myf5 contradicts previous 
literature. Previous work by Sun et al. 2010 [118] also in mouse myoblasts showed that MyoD 
transcriptional levels and protein expression was reduced in the presence of rapamycin, 
indicating a role for a rapamycin-sensitive mTOR complex in the regulation of MyoD 
expression. Thus, the role of mTOR in regulating skeletal muscle differentiation is ambiguous, 
although the literature currently presented suggests mTOR may not be involved in mediating the 
effect of leucine presence on mouse myoblast differentiation. 
The study by Dai et al. 2015 [7] also examined the role of rapamycin-sensitive mTOR in 
mediating the effect of leucine on rat muscle satellite cell differentiation. Interestingly, their 
results showed that rapamycin treatment inhibited MyoD expression in response to leucine 
treatment indicating a role of rapamycin-sensitive mTOR in regulating MyoD. Conversely, 
rapamycin-sensitive mTOR was not involved in regulating the increase in myogenin protein 
expression in response to leucine treatment. Thus, they concluded that rapamycin-sensitive 
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mTOR was critical in mediating at least some part of muscle differentiation in response to 
leucine.  
Clearly, there appears to be some controversy about the role of rapamycin-sensitive 
mTOR in mediating the effect of leucine on the skeletal muscle differentiation program. Averous 
et al. 2012 [6] themselves mentioned they could not find an explanation for their contradictory 
results compared to the similar study by Dai et al. 2015 [7]. There is also a paucity of research 
that examines the mechanism by which mTOR activation causes transcriptional regulation of 
Myf5, MyoD, and myogenin during myoblast differentiation, and if any other pathways mediate 
this interaction. Further investigation is warranted to draw a clearer picture of the mechanisms 
that regulate muscle differentiation in response to leucine.   
 
5.0 Branched-chain amino acid metabolism 
It has been clearly shown that branched-chain amino acids can positively regulate aspects 
of existing skeletal muscle metabolism and skeletal muscle differentiation. What is not clear is 
how these effects are achieved, including the intermediates that facilitate this process. In various 
tissues, including skeletal muscle, all three BCAAs undergo similar multi-step catabolic 
pathways that yield various metabolites. There is evidence to believe that these metabolites of 
BCAAs are also responsible for mediating at least some aspects of the anabolic effects observed 
in response to BCAAs. In this section, evidence will be presented that implicates products of 
BCAA catabolism in regulating skeletal muscle anabolism, as well as information regarding the 
characteristics, function, and regulation of the catabolic pathways and their intermediates.  
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5.1 BCAA catabolic pathways 
The first step of leucine, isoleucine, and valine catabolism involves the reversible 
transamination of these amino acids to their α-keto acid derivatives via the branched-chain 
amino transferase (BCAT) enzyme. Transamination of leucine produces α-ketoisocaproate 
(KIC), of isoleucine produces α-keto-methylvalerate (KMV), and of valine produces α-
ketoisovalerate (KIV). At the same time that the BCAT enzyme removes the amino group from a 
BCAA, it donates the amino group removed to α-ketoglutarate to produce glutamate. Glutamate 
can then be converted to glutamine via glutamine synthetase (GS). Thus, not only is BCAT 
important in catabolizing the BCAAs, but it is also important in supporting glutamine synthesis 
[166]. The reverse reaction of glutamate to α-ketoglutarate by alanine transaminase (AT) 
simultaneously catalyzes the conversion of pyruvate to alanine. The liver can uptake alanine 
from the blood, and use the alanine to produce pyruvate to be used in gluconeogenesis. 
Glutamate can also be converted back to α-ketoglutarate in the liver, which removes the amino 
group and produces urea to be excreted. Thus, BCAA catabolism allows nitrogen cycling that 
allows various substrates to be produced and used in other reactions in skeletal muscle and the 
liver. This paradigm is illustrated in Figure 2.  
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Figure 2: The three BCAAs share a similar initial step in their catabolism. The branched-chain amino 
transferase (BCAT) enzyme reversibly transaminates BCAAs to yield corresponding α-keto acids. This 
reaction simultaneously donates an amino group to α-ketoglutarate to yield glutamate (Glu). Glutamate can 
then be used to produce glutamine in skeletal muscle via glutamate synthetase (GS). Glutamate can also 
be converted back to α-ketoglutarate using pyruvate, to produce alanine. Alanine can then travel in the 
blood to the liver where alanine transaminase (AT) can deaminate alanine back to pyruvate to be used in 
gluconeogenesis. In the liver, glutamate dehydrogenase (GD) disposes of the amino group transferred from 
alanine to glutamate by producing urea.  
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The branched-chain α-keto acids (KMV, KIV, and KIC) produced by BCAT in the first 
transamination reaction can themselves be further catabolized in a separate pathway. The three 
branched-chain α-keto acids (BCKAs) are irreversibly decarboxylated by the branched-chain α-
keto acid dehydrogenase complex (BCKDC or BCKD or BCKAD) to produce acyl-CoA 
derivatives with one less carbon. The subsequent pathways resemble those for fatty acid 
oxidation, and produce metabolites that can be used in the tricarboxylic acid cycle. KMV (from 
isoleucine) catabolism ultimately produces propionyl-CoA and acetyl-CoA, which are 
respectively glucogenic and ketogenic products. KIC (from leucine) catabolism yields acetyl-
CoA and acetoacetate, which are ketogenic. KIV (from valine) finally produces succinyl-CoA 
and is therefore glucogenic. In the liver, KIC can also be catabolized by the KIC-dioxygenase 
enzyme through a separate pathway to produce the metabolite β-hydroxy-β-methylbutyrate 
(HMB) [167].  (Figure 3). 
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5.2 BCAT structure and distribution  
The branched-chain aminotransferase enzyme occupies both the cytosol and 
mitochondria. The mitochondrial isozyme, BCAT2 or BCATm, exists in most rat tissues but is 
not found in the liver or brain. The cytosolic isozyme, BCAT1 or BCATc, exists only in the 
brain, liver, and has been detected at lower levels in rat testes, ovary, and placenta [168]. The 
Michaelis constants (Km) for the mitochondrial and cytosolic enzymes differ little in rat brain, 
kidney, skeletal muscle, and mammary glands [169]. In various tissues, both enzymes also show 
the highest affinity towards leucine and isoleucine with a Km ranging from 0.4 to 0.8mM, 
followed by 1.2 to 4mM for valine [169], [170]. In rats, total BCAT activity per gram of tissue is 
believed to be highest in the heart and kidney, intermediary in skeletal muscle, and lowest in the 
liver [171]. In humans, BCAT activity is highest in the kidney, intermediary in the brain and 
stomach, and lowest in the heart, muscle, liver, and intestines [172]. However, since skeletal 
muscle represents a much larger portion of tissue relative to the body, skeletal muscle is 
responsible for the bulk of BCAA transamination. The BCAT enzymes contain a redox-sensitive 
CXXC center that plays an important role in enabling its catalytic activity. The C’s represent 
cysteine residues while the X’s represent other amino acids. The significance of these residues is 
that they allow the BCAT enzymes to catalyze both forward and reverse transamination between 
BCAAs and BCKAs [173].  
Figure 3. The first step in branched-chain amino acid catabolism is transamination by the BCAT enzyme to produce 
a corresponding α-keto acid. The BCKD complex then irreversibly decarboxylates keto acids to produce 
corresponding CoA derivatives. In the liver, KIC can also be metabolized by the KIC-dixoygenase cytosolic enzyme 
to produce β-hydroxy-β-methylbutyrate (HMB). Modified from She P, Olson KC, Kadota Y, Inukai A, Shimomura Y, 
Hoppel CL, Adams SH, Kawamata Y, Matsumoto H, Sakai R, Lang CH, Lynch CJ. Leucine and protein metabolism 
in obese Zucker rats. PLoS One. 2013;8(3) [219] 
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5.2.1 Regulation of BCAT 
There are currently no unique mechanisms that have been identified to regulate BCAT2 
or BCAT1 activity. Thus, its enzymatic activity primarily depends on the concentration of the 
enzyme and its substrates [174]. BCAT enzymes operate close to equilibrium in most tissues, 
with the concentrations of product and substrate being at or below the Km value [175]. Because 
the Km of BCAT for α-ketoglutarate is lower than the Km for the BCAAs, there is a higher 
potential for α-ketoglutarate to become the limiting substrate for transamination [174]. In this 
situation, re-amination of BCKAs via the reverse reaction to reproduce α-ketoglutarate would be 
expected [174]. Both BCAT2 and BCAT1 also use Vitamin B-6 cofactors to catalyze 
transamination [176]. Since the rate of reaction for BCAT depends on reactant and product 
concentrations, BCKAs must be eliminated from the tissue for the forward transamination 
reaction to proceed. This can occur via transport of the BCKAs out of the cell, or by catabolism 
of the BCKAs via the second catabolic step. The second catabolic step in BCAA metabolism is 
mediated by the BCKD enzyme and involves irreversible decarboxylation of BCKAs as 
previously described.  
5.3 BCKD structure and distribution  
 Once BCAAs are transaminated by the BCAT enzyme, the BCKD enzyme complex can 
further catabolize the α-keto acid produced.  The structure and function of BCKD is said to 
resemble that of the pyruvate dehydrogenase complex, and is comprised of 3 enzyme subunits 
[174]. The branched-chain α-keto acid decarboxylase is identified as the E1 (α2β2) subunit, the 
dihydrolipoyl transacylase as the E2 subunit, and the dihydrolipoyl dehydrogenase as the E3 
subunit. It is the E1 subunit that catalyzes the decarboxylation of BCKAs, and uses thiamine 
diphosphate (ThDP) as a cofactor. BCKD also requires coenzyme A (CoA) and NAD+ as 
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cofactors, and is located within the inner mitochondrial wall. Similar to BCAT, BCKD can 
catabolize the products of all three BCAAs. However, unlike BCAT2 which allows reversible 
transamination, the decarboxylation by BCKD is an irreversible and rate-limiting step. In rat 
liver, BCKD has been shown to have a higher affinity towards KIC and KMV (BCKAs of 
leucine and isoleucine) with a Km of 15 and 14 µm, respectively. BCKD has a lower affinity for 
KIV (BCKA of valine), with a Km of 28 µm [177]. BCKD is present in all cells throughout the 
body and has been found to have varying activity levels in different tissues and different animals. 
In rats, BCKD oxidative activity has been found to be highest in the liver, followed by the 
kidney, and lowest in skeletal muscle, brain, and intestines. In humans, BCKD activity is highest 
in skeletal muscle, followed by the brain and liver, and lowest in the kidney, and stomach [172]. 
Unlike BCAT which has no identified regulators, the BCKD complex has been found to be 
regulated by multiple mechanisms. 
 5.3.1 Regulation of BCKD 
 The BCKD complex can be regulated by inhibitory or activating 
phosphorylation/dephosphorylation by distinct protein kinases. The branched-chain α-keto acid 
dehydrogenase kinase (BCKDK) enzyme phosphorylates the E1 subunit of BCKD and causes 
inhibition of BCKD activity. There are at least three phosphorylation sites on the E1α subunit 
that can be phosphorylated by BCKD kinase. Phosphorylation on Ser293, Ser332, and Ser337 blocks 
the binding site for BCKAs and inhibits the function of the BCKD complex [178], [179]. BCKD 
kinase expression has been found to be regulated by exercise, diet, and hormonal state. BCKD 
kinase activity decreases in response to exercise, high-protein diets, and insulin withdrawal 
(reviewed in [180]. The net effect of reduced BCDK kinase activity is increased BCKA 
oxidation under these circumstances. BCKD kinase can also be directly inhibited by KIC 
 35 
accumulation [181]. Conversely, BCKD kinase activity can be increased by starvation, low-
protein diets, and insulin presence, and results in decreased BCKA oxidation [180], [182]. While 
BCKD can be inactivated by BCKD kinase, it can be activated by the mitochondrial isoform of 
protein phosphatase 1K (PPM1K, also known as PP2CM). Under conditions of excess BCAA, 
the phosphorylation of Ser293 on the E1α subunit of BCKD becomes dephosphorylated by 
PPM1K [179]. PPM1K is regulated at the transcriptional level in response to nutrient status. In 
mice, nutrient deprivation and BCAA depletion causes down-regulation of PPM1K mRNA 
[183]. Lastly, BCKD activity is also regulated by its end products. NADH and the branched-
chain acyl-CoA derivatives produced can competitively inhibit the BCKD complex and prevent 
further BCKA oxidation [184]. 
5.4 Auxiliary regulation of BCAA catabolism  
 Although factors such as nutrient presence, exercise, and insulin can regulate the BCAA 
catabolic enzymes, pathways that mediate this phenomenon have not been completely 
elucidated. Recently, Zhen et al. 2016 [185] attempted to identify targets that mediate BCKD 
activity in response to the BCAA leucine. They found that oral administration of a 2% leucine 
solution in 7-week-old mice resulted in a significant increase in heart BCKD activity. However, 
when they provided the leucine solution to mice that were simultaneously treated with 
rapamycin, they observed that there was no increase in BCKD activity. Thus, this study suggests 
that a rapamycin-sensitive mTOR complex regulates BCKD responsiveness to BCAAs.  
  It is known that exercise promotes BCAA oxidation via upregulation of BCAA catabolic 
enzymes [186]. It is also known that exercise can promote mitochondrial function and biogenesis 
via the PPAR γ coactivator of 1α (PGC-1α) [187]. Hatazawa et al. 2014 [188] sought to 
determine if PGC-1α can regulate BCAA metabolism by affecting the expression of its key 
 36 
catabolic enzymes. To do this, they created a model of transgenic mice overexpressing PGC-1α 
and examined the regulation of BCAT2, BCKD, and BCKDK, in skeletal muscle. Compared to 
WT mice, they found a significant increase in the mRNA expression of BCAT2, BCKD, but no 
change in BCKDK. When examining the protein expression, they correspondingly observed an 
increase in BCKD, but no change in BCKDK. Oddly, the study did not present any data on 
BCAT2 protein expression. When examining BCAA levels, they found decreased levels of 
valine and leucine along with increased levels of glutamic acid/glutamate (a metabolite of 
BCAT2). These findings support the notion that transgenic mice overexpressing PGC-1α have 
increased BCAA catabolism. Their experiments in C2C12 mouse myoblasts that were 
overexpressing PGC-1α cells yielded similar results. Thus, this study provides evidence that 
PGC-1α can control BCAA catabolism by positively regulating the expression of BCAA 
catabolic enzymes.  
 Adiponectin is another molecule which has been shown to regulate BCAA catabolism. 
Adiponectin is an adipocytokine that helps regulate proper glucose and lipid metabolism [189], 
[190]. In cases of insulin attenuation, such as diabetes, adiponectin levels are decreased [191]. 
BCAA metabolism can also be regulated by insulin levels [180], [182]. Based on these findings, 
Lian et al. 2015 [192] tried to determine if there was any connection between adiponectin and 
BCAA metabolism. They demonstrated that mice that were adiponectin deficient and diabetic 
exhibited significantly decreased BCKD activity along with decreased PPM1K (PP2CM) protein 
levels. This was complemented with an increase in BCKD kinase expression, and a concurrent 
increase in plasma BCAAs and BCKAs.  Interestingly, subsequent treatment with adiponectin in 
these mice restored the expression of PPM1K, BCKD, along with BCKD activity, and BCAA 
and BCKA levels. Lastly, the adiponectin-mediated amelioration in PPM1K expression and 
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BCKD activity were eliminated when AMPK (a kinase that plays a role in cell energy 
homeostasis) was inhibited. Conclusively, the work by Lian et al. 2015 [192] showed that 
adiponectin-AMPK signaling is required for adequate function of BCAA catabolism. 
Furthermore, the dysregulation of BCAA metabolism in cases of diabetes may be in part due to 
the fact that there is reduced adiponectin.  
 Despite being separate enzymes with distinct functions, Islam et al. have shown that 
BCATm and BCKD can directly interact with one another to form a structural relationship 
referred to as a metabolon. Islam et al. 2007 [193] found that human BCATm can directly 
associate with the E1 decarboxylase component of either rat or human BCKD. NADH, a 
metabolite of BCKD, dissociates the complex. Furthermore, they found the rate of E1-catalyzed 
decarboxylation was enhanced 12-fold when BCATm was also present. In a separate study by 
the same group, they demonstrated that the binding of BCATm to the E1 decarboxylase allows 
direct channeling of BCKAs from BCATm to BCKD [194].  This evidence suggests that there is 
direct cooperativity between BCAT and BCKD to facilitate BCAA/BCKA oxidation, and the 
presence of one can enhance the function of the other.  
 
6.0 BCAA metabolites and skeletal muscle anabolism 
 As covered in section 4, branched-chain amino acids can positively regulate many 
aspects of skeletal muscle anabolism. However, it is not entirely clear whether it is BCAAs 
themselves or products made from BCAAs that regulate muscle anabolism. Interestingly, there is 
evidence that suggests the metabolites of BCAAs, particularly those of leucine, play important 
roles in mediating the anabolic effects of BCAAs in skeletal muscle. In this section, studies 
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examining the roles of the metabolites of BCAAs on skeletal muscle hypertrophy and skeletal 
muscle differentiation will be reviewed.  
6.1 BCAA metabolites and skeletal muscle hypertrophy 
One of the most well characterized BCAA metabolites that has anabolic effects on 
existing skeletal muscle tissue is the leucine metabolite β-hydroxy-β-methylbutyrate (HMB). 
HMB is a metabolite produced from KIC decarboxylation via the liver KIC-dixoygenase enzyme 
(Figure 3). In 1996, Nissen et al. [8] were the first to show that supplementing HMB to 
individuals undertaking resistance exercise enhanced gains in lean body mass and strength, while 
lowering rates of post-workout muscle proteolysis. Since then, numerous studies have examined 
the effects of HMB in different cohorts. HMB supplementation has been shown to promote gains 
in lean body mass, strength, aerobic performance, in trained, untrained, elderly, and sedentary 
populations (reviewed in [9]). The anabolic effects of HMB in existing muscle have been shown 
to be mediated in part by the mTORC1 pathway. Eley et al. 2007 [10] demonstrated that HMB 
supplementation was able to induce protein synthesis in mouse myoblasts. This increase in 
protein synthesis correlated with an increase in phosphorylation of mTOR along with p70-S6K1 
and 4E-BP1 (targets that regulate mRNA translation; see section 2.5). Furthermore, the increase 
in protein synthesis was abolished in the presence of rapamycin (an mTORC1 inhibitor). Aversa 
et al. 2011 [11] also showed that HMB supplementation promotes protein synthesis in rats in an 
mTOR-dependent manner. Similar to leucine, HMB can also suppress dexamethasone and 
cancer-induced muscle proteolysis via down-regulation of the ubiquitin-proteasome system and 
its atrogenes MuRF-1 and atrogin-1 [195]–[197]. Clearly, many of the positive effects seen with 
leucine treatment in muscle (described in section 4) can be emulated by its metabolite HMB.  
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The leucine metabolite KIC (α-ketoisocaproate) has also been shown to stimulate 
anabolic mechanisms in muscle. Escobar et al. 2010 [12] sought to compare the effect of leucine 
vs. KIC administration in neonatal pigs. Infusion of leucine or KIC (400µm/kg) both resulted in 
a ~60% increase in longissimus dorsi muscle protein synthesis compared to mock infused 
piglets. Both leucine and KIC also caused a 3-fold increase in 4E-BP1 phosphorylation and 
eIF4E/eIF4G complex formation in muscle tissues, compared to control. This study suggests 
KIC can mimic leucine-induced stimulation of protein synthesis and regulation of mTOR 
signaling. Another study by Tischler et al. 1981 [13] examined the role of leucine and its 
catabolism in regulating protein synthesis and protein degradation in rat diaphragm and cardiac 
muscle. They observed that administration of 0.2 to 0.5 mM of leucine was able to both increase 
protein synthesis and prevent breakdown (measured by 14C labeled amino acid incorporation and 
release). To determine if leucine catabolism was required for these effects, they inhibited the 
BCAT2 enzyme with the drug L-cycloserine. Recall that BCAT2 transaminates leucine (along 
with valine and isoleucine) to produce corresponding BCKAs. L-cycloserine treatment 
completely blocked the attenuation of protein degradation observed with leucine treatment in 
both diaphragm and atrial muscle. This result suggests that KIC and/or other metabolites of 
BCAA catabolism mediate BCAA-induced attenuation of skeletal muscle atrophy. Interestingly, 
L-cycloserine treatment did not affect leucine-induced stimulation of protein synthesis, 
suggesting leucine itself is responsible for the stimulation of protein synthesis in rat diaphragm 
and atrial muscle. Nonetheless, the overall findings of these studies implicate a role for BCAA 
metabolites, particularly those of leucine, in mediating the anabolic effects seen with BCAA 
supplementation in skeletal muscle.   
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6.2 BCAA metabolites and skeletal muscle differentiation 
Metabolites of BCAAs have been shown to have similar anabolic properties as their 
branched-chain amino acid precursors in existing skeletal muscle.  In regards to skeletal muscle 
differentiation, there is evidence to suggest that BCAA metabolites also have anabolic properties. 
Kornasio et al. 2009 [14] demonstrated that supplementing HMB to serum-starved human and 
chick myoblasts stimulated their proliferation and differentiation in a dose-dependent manner. In 
serum-starved chicken and human cells, HMB administration for 17 hours caused increased cell 
number and DNA synthesis (markers of cell proliferation), along with increased MyoD mRNA 
and protein accumulation. 24 hours of HMB treatment to serum-starved cells caused an increase 
in the levels of muscle differentiation factors myogenin and MEF2 in chicken myoblasts. Myosin 
Heavy Chain (MHC) levels were also increased in both chicken and human myoblasts in a dose-
dependent manner. Cell fusion was also observed in the C2 mouse myogenic line in response to 
HMB treatment. At higher levels of HMB, a significant increase in the number of myotubes 
containing five or more nuclei was observed. Lastly, HMB treatment was found to increase 
levels of IGF-1, along with MAPK/ERK signaling and AKT signaling. Thus, this study provides 
evidence the leucine metabolite HMB can alone promote skeletal muscle myoblast proliferation 
and differentiation, and upregulate pathways that induce these effects. Unfortunately, this was 
the only study that was found that examined the specific effect of a BCAA metabolite on skeletal 
muscle differentiation.  
 
7.0 Disruption of branched-chain amino acid catabolism  
Because metabolites of BCAAs have been shown to possess important anabolic 
properties in skeletal muscle hypertrophy and skeletal muscle differentiation, the enzymes that 
produce these metabolites likely have great importance in facilitating muscle anabolism. This 
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section will review studies that have examined the effects of disrupting the BCAA catabolic 
enzymes (BCAT and BCKD) in muscle. 
7.1 Disruption of BCAT 
 She et al. 2007 [198] conducted a study in which they sought to determine the 
effect of a whole body BCAT2 knockout in mice. Knockout mice grew at the same rate as wild-
type (WT) mice up until ~6 weeks, after which the knockout mice exhibited a 10-15% reduction 
in body weight compared to WT. The loss in body mass was found to be from reduced 
epididymal fat and kidney weight. There was no reduction in gastrocnemius muscle, liver, or 
heart mass. Knockout mice also consumed less of the normal chow diet than WT mice, but 
consumed more of the BCAA-free chow than WT mice. Although knockout mice consumed less 
BCAAs, their plasma leucine, isoleucine, and valine levels were increased 14, 21, and 31 fold, 
respectively. Interestingly, knockout mice were also protected from diet-induced obesity, as 
feeding mice a high fat diet for 15 weeks resulted in knockout mice that were still significantly 
leaner than WT mice. Plasma levels of the BCAA transamination product KIC was not changed, 
whereas KMV and KIV levels were reduced. The leanness of BCAT knockout mice was found 
to be a result of increased energy expenditure. In regards to the effect of BCAT knockout on 
skeletal muscle, it was found that both protein synthesis and protein degradation was 
significantly higher in gastrocnemius muscle, indicating higher rates of protein turnover, 
although muscle weight was not changed. The increased rate of protein turnover was found to 
correlate with increased mTOR signaling as indicated by higher phosphorylation of the mTOR 
downstream targets 4E-BP1 and rpS6. Surprisingly, the results from this study do not convey any 
negative consequences for skeletal muscle as a result of BCAT knockout. Although there was an 
increased protein turnover rate, there was no difference in gastrocnemius muscle mass or general 
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locomotor activity.  In fact, BCAT2 knockout provides mice with an advantage of being 
protected from diet-induced obesity via increased energy expenditure. It should be noted that this 
study only looked at the change in mass of one muscle (gastrocnemius), and did not measure 
other functional measurements of muscle such as strength and endurance.  
In a separate study, however, She et al. 2010 [15] examined the effect of BCAT2 
knockout (KO) on exercise metabolism and endurance in mice. These mice were subjected to 
inclined treadmill running to exhaustion. They observed that BCAT2 knockout mice had 
significantly lower running times and running distances. Additionally, it was observed that this 
impairment in BCAT2 KO mice coincided with a decrease in glutamine levels, and increase in 
lactate and ammonia production. Thus, BCAT2 disruption likely can impair metabolic 
homeostasis in skeletal muscle that can negatively affect skeletal muscle performance. They also 
observed no change to structural components of muscle fibers in BCAT2 KO mice, further 
suggesting it is impaired muscle metabolism that contributes to exercise impairment.  
7.2 Disruption of BCKD 
There are multiple studies that have investigated impaired BCKD function, since this 
enzyme serves as the rate limiting irreversible step in BCAA oxidation and because it is 
regulated by various mechanisms. Mutations in genes encoding subunits of the BCKD complex 
or PPM1K can lead to a condition known as maple syrup urine disease (MSUD). The name of 
the disease is in reference to the sweet smelling urine that results from increased concentrations 
of BCAAs/BCKAs. Human and animal models of MSUD both show elevated levels of BCAA 
and BCKAs [199], [200]. Although the disease can be managed by eating a low protein diet, this 
disease can produce deleterious effects if not treated promptly. Neural cell models of MSUD 
exhibit increased oxidative stress and mitochondrial dysfunction in response to BCKAs [201], 
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[202], which can serve as a contributor to brain damage seen in MSUD patients [203]. Neural 
cells and fibroblasts isolated from patients with MSUD also undergo apoptosis in response to 
BCKAs [204], [205]. In regards to possible effects on muscle, zebra fish with MSUD show 
dysfunctional locomotor activity that results in aberrant swimming behavior [18]. Clinical 
reports also show that adult human patients can develop muscle dystonia [19], and newborns 
with the disease can display hypotonia and develop muscle spasms [17]. Quadriceps femoris 
muscle biopsies from these newborns show that some of their muscle fibers have irregular shapes 
along with nuclei that are abnormally large and also irregularly shaped. There were muscle fibers 
that also showed indications of myofibrillar destruction indicated by damage to sarcomeres, and 
in some instances damaged fibers were converted to empty sarcolemmic sacs. Thus, MSUD, 
which involves dysregulation of the BCKD enzyme, can produce negative consequences for 
skeletal muscle, among other tissues. 
On the other side of the spectrum, hyperactivity of the BCKD complex can also produce 
negative effects. Joshi et al. 2006 [206] developed a transgenic mouse line that was deficient for 
the BCKD kinase (BCKDK). Recall that the BCKD kinase mediates inhibitory phosphorylation 
of the BCKD complex enzyme, thus these mice had hyperactive BCKD activity. These mice had 
lower plasma and tissue levels of BCAAs, and by 12 weeks of age were 15% smaller than wild-
type mice. Muscle, brain, and adipose tissue weights were attenuated in knockout mice, whereas 
liver and kidney weights were elevated. These mice had abnormal hindlimb flexion throughout 
life, and developed epileptic seizures after 6-7 months of age, indicating defects in neurological 
and/or neuromuscular systems.  
Conclusively, the negative consequences of BCKD disruption and BCKD hyper 
activation indicate that adequate BCKD regulation is an important process in many tissues 
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including skeletal muscle. The role of BCKD disruption in skeletal muscle differentiation is not 
known, although, the fact that newborn infants with MSUD have defective muscle tissue 
indicates that defective embryonic myogenesis due to disrupted BCKD function is likely to 
blame.  
 
SUMMARY 
Skeletal muscle differentiation is a process by which precursor muscle cells called 
myoblasts mature and fuse with one another to form myotubes, which themselves can further 
develop to form skeletal muscle fibers. Skeletal muscle differentiation is an important process 
that enables the formation of new muscle tissue during embryo development or after muscle 
injury/damage.  
Skeletal muscle differentiation is regulated by many pathways, some of which are 
responsive to nutrient presence. Specifically, amino acid presence can regulate and stimulate 
skeletal muscle differentiation. Out of all amino acids, the branched-chain amino acids, 
particularly leucine, have been shown to potently stimulate anabolic pathways and suppress 
atrophic pathways in skeletal muscle hypertrophy and differentiation.  
One of the major questions is how BCAAs, particularly leucine, exert their anabolic 
effects in skeletal muscle differentiation. There is evidence that suggests that it may be in part 
due to the metabolites that are produced from BCAA catabolism, as these metabolites themselves 
have been shown to exert similar anabolic and anti-catabolic effects. Furthermore, disruption of 
BCAA catabolism in models of existing muscle tissue exhibit impaired skeletal muscle function, 
structure, and metabolism. Thus, BCAA catabolism likely represents a critical process in the 
maintenance and growth of existing muscle tissue. However, the importance of BCAA 
 45 
catabolism during skeletal muscle differentiation, where new muscle tissue is being formed, is 
not known.  
 
RESEARCH OBJECTIVES  
 The aim of our study was to examine the role of branched-chain amino acid catabolism in 
skeletal muscle differentiation. Previous research has shown that branched-chain amino acids, 
particularly leucine, can positively regulate skeletal muscle hypertrophy and skeletal muscle 
differentiation. Studies that examine metabolites of leucine catabolism also show that these 
metabolites can induce anabolic effects similar to leucine in both skeletal muscle hypertrophy 
and skeletal muscle differentiation. Furthermore, models of disrupted BCAA catabolism, such as 
in maple syrup urine disease, exhibit compromised skeletal muscle structure and function. Thus, 
we wondered if BCAA catabolism is critical in mediating the anabolic effect of BCAA presence 
in skeletal muscle differentiation. In this study, we aim to complete the following objectives:  
 1) Although the leucine metabolite HMB has been shown to regulate skeletal muscle 
differentiation, the leucine metabolite KIC has not been studied in this context. Thus, we aim to 
determine if KIC can also regulate skeletal muscle differentiation. 
2) Expression levels of enzymes that mediate BCAA catabolism during skeletal muscle 
differentiation are not known. Hence, we seek to elucidate the expression of both muscle specific 
isoform of BCAT (BCAT2), and BCKD during skeletal muscle differentiation.  
3) The role of BCAA catabolism in skeletal muscle differentiation is not known. We 
attempt to examine how skeletal muscle differentiation is affected by disrupting the BCAA 
catabolic enzymes, BCAT2 and BCKD.  
To attain these objectives, we utilized an in-vitro model of differentiating rat skeletal 
muscle myoblasts for a period of five days. Under normal conditions, these myoblasts can 
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differentiate and fuse with one another to form elongated premature muscle fibers called 
myotubes. We conducted various experiments throughout this model of differentiation and 
ultimately attempted to determine if BCAA catabolism regulates this process.  
 
HYPOTHESES 
1) Based on literature that suggests KIC can regulate skeletal muscle hypertrophy to a 
similar extent as leucine, I hypothesize that KIC will be able to also regulate skeletal 
muscle differentiation. 
2) Based on previous literature that suggests that BCAA metabolites can positively 
regulate skeletal muscle differentiation, I hypothesize that expression of BCAT2 and 
BCKD will increase during myoblast differentiation so as to produce higher levels of 
their metabolites. 
3) It has been shown that whole-body animal knockouts of BCAT2 demonstrate 
disrupted muscle energy metabolism and exercise capacity. Thus, I hypothesize that 
disrupting BCAT2 during skeletal muscle differentiation will disrupt myoblast 
differentiation. In regards to BCKD, it has been shown that disruption of BCKD 
negatively affects skeletal muscle structure and function, thus I hypothesize that 
disrupting BCKD in myoblasts will also negatively affect skeletal muscle 
differentiation.  
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EXPERIMENTAL DESIGN & MATERIALS 
Cell culture & differentiation protocol: To produce a model of skeletal muscle cell 
differentiation, we cultured L6 rat myoblasts and differentiated them for a period of 5 days. L6 
rat myoblasts were obtained from the American Type Culture Collection. Approximately 5.0 x 
105 cells were seeded in a 10-cm plate and incubated at 37ºC and 5% CO2. The growth medium 
(GM) was α–modified MEM (AMEM) obtained from Wisent Bioproducts (#310-010-CL), 
supplemented with 10% fetal bovine serum (Gibco #10082147) and 1% antibiotic-antimycotic 
(Ab) (Wisent #450-115-EL). Cells were passed every 48 hours or at approximately 70% 
confluency. To initiate differentiation, cells were first grown to ~90% confluency. Cells were 
then shifted to a differentiation medium (DM) consisting of AMEM, 1% antibiotic-antimycotic, 
and 2% horse serum (Gibco # 26050088). The differentiation medium was replaced every 24 
hours.  
Leucine deprivation + KIC rescue experiment: To observe how differentiation was affected by 
depriving myoblasts of leucine, the following was conducted: 1.5 x 105 cells were seeded in 6-
well plates using growth media (AMEM + 10% FBS+ 1%Ab). Once cells reached ~90% 
confluency, the media was shifted to differentiation media consisting of RPMI 1640 (US 
Biologicals R8999-03), + 2% HS + 1% Ab. RPMI media was used because it lacks L-leucine 
(along with L-glutamine, L-alanine, and sodium bicarbonate). L-glutamine and sodium 
bicarbonate were re-added to all RPMI media at concentrations to mimic AMEM. L-leucine and 
L-alanine were added to respective treatments to replicate AMEM concentrations. RPMI 
differentiation media was changed every 24 hours. To examine the effect of adding the leucine 
metabolite KIC to leucine-deprived cells, the following was conducted: cells were differentiated 
in media that was leucine-free but supplemented with 200 µM of α-ketoisocaproate (KIC) 
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(Sigma #K0629). The supplemented differentiation media was changed every 24 hours.  
Following all treatments, cells were washed with cold PBS and harvested with 100µl lysis buffer 
and stored at -20ºC. The lysis buffer was formulation was: 1mM EDTA, 2% sodium dodecyl 
sulfate (SDS), 25mM Tris, protease cocktail inhibitor (10 µL/mL) (Sigma #P8340), phosphatase 
inhibitor cocktail (10 µL/mL) (Sigma #P5726), and DTT (1 µL/ml) .  
Western blotting: To obtain protein expression levels of various proteins during the 
differentiation protocol, samples harvested from each treatment day were subjected to western 
blots. Sample protein concentrations were first determined using the Pierce BCA Protein Assay 
Kit (Thermo Scientific #OJI94919). Samples were then mixed with 4x laemmli loading buffer at 
a ratio of 3 parts sample to 1 part buffer. Samples were run on either 10% or 15% SDS-page gels 
and transferred to PVDF membranes. MHC-1, BCKDE1α, and troponin were blotted using the 
10% gel membranes, whereas, BCAT2, ph-S6, caspase-3, and myogenin were blotted using the 
15% gel membranes. Membranes were incubated for 1 hour in 5% non-fat milk at room 
temperature. Membranes were then washed twice briefly and then once for 5 minutes with TBS-
T, then incubated with primary antibody diluted in 2.5% BSA overnight at 4ºC. Following this, 
membranes were again washed twice briefly and then another three times for 5 minutes each 
with TBS-T, then incubated in either rabbit or mouse secondary antibody diluted in 5% non-fat 
milk for 3 hours at room temperature. Membranes were then washed again twice briefly 
followed by three 5-minute rinses, then incubated with HRP chemiluminescent substrate 
(Millipore #WBKLS0500). Immediately after, luminescence was detected using the Kodak 
Image Station 4000mm Pro & Carestream molecular imaging software. Primary antibodies: 
Myosin Heavy Chain-1 1:500 dilution (Developmental Studies Hybridoma Bank #MF20), 
Troponin 1:500 dilution (Developmental Studies Hybridoma Bank #CT3), Myogenin 1:500 
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dilution (Developmental Studies Hybridoma Bank #F5D), BCKDE1α 1:2500 dilution (Sigma 
#SAB2702057), BCAT2 1:3000 (Sigma #B7312), ph-S6 1:3000 dilution (CST #4858), Gamma 
Tubulin 1:10,000 (Sigma #T6557), Caspase-3 1:2000 dilution (CST #9662). Secondary 
Antibodies: Anti-rabbit IgG-HRP-conjugated (CST #7074), Anti-mouse IgG-HRP-conjugated 
(CST #7076); 1:10,000 dilutions. 
mRNA analysis: To observe mRNA levels of BCAT2 and BCKDE1α during myoblast 
differentiation, the following was conducted:  1.5 x 105 cells were seeded in 6-well plates using 
growth media (AMEM + 10% FBS+ 1%Ab). Once cells reached ~90% confluency, the media 
was shifted to differentiation media consisting of (AMEM + 2%HS + 1%Ab). RNA was isolated 
from sample wells using an RNA isolation kit (Thermo-Fisher #12183018A). The RNA isolation 
procedure was carried out according to the manufacturer’s instructions except for the fact that the 
reaction mixture was incubated at 42°C for 60 mins instead of 30 mins. After RNA was isolated 
it was stored at -80°C. cDNA was synthesized from RNA using a cDNA synthesis kit (Bio-rad 
#1725038), and the procedure was also followed according to the provided protocol. Quantitative 
PCR was conducted in 20μl reactions using a kit according to manufacturer’s instructions (Bio-
Rad #1725271), and analyzed using a real-time detection system (Bio-Rad CFX96™). The 
following primers were used: BCAT2 [Forward: 5’-TCCAGAACCTCACAGTGC-3’ Reverse: 
5’-CCTGCTTGTCAAAGTCTG-3’], BCKDE1α [Forward: 5’-GGGCTTGGCTAGATTCA-3’ 
Reverse: 5’-GGGGATCTTCACTGGGGT-3’], HPRT [Forward: 5’-
GCTTTCCTTGGTCAAGCAC-3’ Reverse: 5’-TCCAACAAAGTCTGGCCTGA-3’].  
Measuring intracellular BCAA concentrations: To measure intracellular levels of BCAAs 
during differentiation the following protocol was followed: Briefly, leucine dehydrogenase can 
catalyze the oxidative deamination of BCAAs to their corresponding α-keto acid. The reaction 
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requires NAD+ and produces NADH in an equal molar ratio to the amount of reactant (BCAA). 
The production of NADH can be measured via a fluorometer and a standard curve can be 
generated using different concentrations of BCAAs. This standard curve can then be used to 
estimate sample concentrations of BCAAs. First, 275 µl of assay buffer containing 0.1 M 
potassium phosphate, 2% EDTA, and 0.1% β-mercaptoethanol is added to wells of a 96-well 
plate. Then 10 µl of 120 mM of NAD+ diluted in 0.1 M sodium carbonate buffer is added to the 
wells. 14 µl of sample or standard is then added to each well and a blank fluorescence reading is 
taken. Then, 10 µl of an enzyme solution [7.7857 units of leucine dehydrogenase diluted in (25 
mM sodium phosphate buffer + 1 mg/ml BSA)] is added to each well. Another blank reading is 
taken, followed by a reading after incubation at 37ºC for 15 minutes.  
siRNA transfection experiments: To examine the effect of disrupting BCAA catabolic enzymes 
on myoblast differentiation, we utilized siRNA reverse transfection to disrupt BCAT2 and 
BCKDE1α. The protocol is as follows: 2.5 x 105 cells were seeded in 6 well plates along with 
either a control or treatment transfection media. The control medium consisted of scrambled 
siRNA (Sigma #SIC001) + lipofectamine RNAiMAX (Life Technologies # 13778150) + Opti-
MEM (Life Technologies #31985070) + 1 ml growth medium without antibiotic at ratios 
according to manufacturer protocol. The treatment media consisted of either BCAT2 siRNA 
(Sigma # NM_022400) or BCKDEIα siRNA (Sigma # NM_012782) + lipofectamine RNAiMAX 
+ Opti-MEM at a similar ratio. Twenty-four hours after transfection, 1 ml of growth medium 
with antibiotic was added to all wells. Cells were incubated in this media for another 24 hours 
and grown to ~90% confluency. Cells were then washed twice with warm PBS and shifted to 
differentiation media. Following treatment, samples were harvested with 100μl lysis buffer, and 
stored at -20ºC for later analysis.  
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Cell viability analysis: We measured cell viability to quantify the relative amount of viable cells 
remaining after BCAT2 and BCKDE1α siRNA transfections. Cell viability was measured in 
siRNA transfected myoblasts using the CCK-8 cell viability assay kit (Sigma #96992). Briefly, 
8.0 x 103 cells were seeded along with transfection media in 96-well tissue culture plates. 
Twenty-four hours after transfection, the transfection solution was removed and replaced with 
100μl of growth medium, and 10μl of CCK-8 solution. The absorbance was read at 450nm using 
a spectrophotometer. 24 hours later, the media of the remaining wells was changed to 100μl of 
DM, and cell viability was measured at each day of differentiation. Cell viability is expressed 
relative to control untreated cells that did not receive any siRNA treatment.  
Increasing number of cells after siRNA transfection experiment: Because BCAT2 siRNA 
transfection reduced the number of viable cells, we wondered if adding more cells could rescue 
BCAT2-disrupted myoblast differentiation. To answer this we conducted the following: 24 hours 
following reverse transfection of control or BCAT2 siRNA in 6-well plates, we trypsinized 3 
wells of the BCAT2 siRNA-treated cells and combined them into one new well. Similarly, for 
the control siRNA treated cells, we trypsinized 1 well and simply moved the cells into 1 new 
well. We only used one well for control cells because cell death was minimal in control cells 
compared to BCAT2 disrupted cells. Once the cells from both treatments were placed in to new 
wells, they were allowed to grow in GM for another 24 hours. Following this, cells were shifted 
to DM and their ability to differentiate was observed. The DM was changed every 24 hours.   
BCKA rescue experiment in BCAT2 siRNA cells: To examine the effect of adding branched-
chain α-keto acids (KIC, KMV, KIV) to BCAT2 disrupted cells, the following was conducted: 
2.5 x 105 cells were seeded in 6-well plates along with either a control or BCAT2 siRNA 
transfection mix (described earlier). Twenty-four hours after transfection, 1 ml of regular GM 
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was added to all wells. In BCAT2 siRNA wells 200µM of KIC, 200 µM of KIV, and 200 µM of 
KMV was also added. After another 24 hours of incubation, the cells were shifted to DM, and 
again KIC, KIV, and KMV was re-added to BCAT2 siRNA wells. The DM was changed every 
subsequent 24 hours, and KIC, KMV, KIV was also re-added to BCAT2 siRNA cells when fresh 
DM was added. 
Statistical analysis: Two-tailed paired t-test was used to assess the difference between two 
groups. One-way ANOVA with Tukey Kramer post-hoc test was conducted on experiments with 
more than two groups. Values are means ± SEM. p< 0.05 was considered significantly different. 
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RESULTS 
The leucine metabolite KIC can regulate L6 myoblast differentiation. 
  We first sought to demonstrate the essentiality of the branched-chain amino acid leucine to L6 rat 
myoblast differentiation. Myoblasts differentiated in a differentiation media (DM) that contained all 
amino acids (CTR) demonstrated a robust ability to differentiate as visible myotubes formed after 5 days 
(D5) of differentiation (Fig. 4A). Myoblasts differentiated in media that lacked the non-essential, non-
BCAA amino acid alanine also were able to differentiate well (Fig. 4A). However, when we tried to 
differentiate myoblasts in media that lacked the BCAA leucine, no differentiation was observed as 
indicated by the absence of myotube formation (Fig. 4A).  The cells also appeared to enter a non-
proliferative and quiescent state. Interestingly, when we added the leucine metabolite α-ketoisocaproate 
(KIC) to leucine-deprived myoblasts, the myoblasts were able to differentiate and form visible myotubes 
(Fig. 4A).  
 We also examined the protein expression of various markers of differentiation in these cells. 
Levels of the myofibrillar proteins myosin heavy chain (MHC) and troponin were both abundantly 
present in CTR and alanine-deprived conditions by D5 of differentiation (Fig. 4B). On the other hand, 
myoblasts differentiated in leucine-free DM showed no expression of MHC or troponin. However, 
myoblasts differentiated in the leucine-free DM supplemented with KIC demonstrated robust MHC and 
troponin expression at D5 (Fig. 4B). Protein level of the myogenic regulatory factor myogenin followed a 
similar expression profile as expression of the myofibrillar proteins. The mTORC1 target S6 (or rpS6) 
that is phosphorylated in response to nutrient stimulation was also found to be hypo-phosphorylated at D5 
in leucine-deprived myoblasts, but phosphorylated in all other conditions (Fig. 4C).  
Conclusively, these results demonstrate the BCAA leucine is essential for L6 myoblast 
differentiation, and furthermore, in the absence of leucine, KIC can rescue myoblast differentiation. KIC 
supplementation can also rescue myofibrillar protein expression, expression of the myogenic regulatory 
factor myogenin, and nutrient-induced mTORC1 signaling.  
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Expression of BCAA catabolic enzymes BCAT2 and BCKD increase during L6 differentiation 
 Because we observed that metabolites of leucine catabolism could regulate L6 myoblast 
differentiation, we wondered how the enzymes that produce BCAA metabolites are regulated during 
myoblast differentiation. Expression of BCAT2 (the BCAT isoform found in skeletal muscle) showed a 
non-significant trend to increase to day 3 (D3) of differentiation (Fig. 5A). Expression of the BCKD 
subunit BCKDE1α showed a significant trend to increase on all days of differentiation, where D4 and D5 
were significantly higher compared to D1 of differentiation (p<0.05) (Fig. 5A). We also investigated 
mRNA levels of BCAT2 and BCKDE1α during differentiation. We found a non-significant increase in 
BCAT2 mRNA at D1 and D4 of differentiation (Fig. 5B). BCKDE1α mRNA analysis showed a trend to 
increase between D0 and D2 of differentiation, followed by a significant decrease to D5 (p<0.05) (Fig. 
5B). In summary, our evidence suggests there is an upregulation of BCAT2 and BCKDE1α transcription 
and protein expression during portions of rat myoblast differentiation.  
 
Intracellular BCAA concentrations do not change during L6 myoblast differentiation 
 Since we observed that levels of the enzymes responsible for BCAA catabolism increase during 
differentiation, we wondered if there were concurrent changes in intracellular concentrations of BCAA. 
We observed no significant difference in levels of BCAAs within myoblasts over the five-day 
differentiation period (Fig. 6). 
 
BCAT2 disruption prevents L6 myoblast differentiation 
 The increase in BCAT2 and BCKD expression during myoblast differentiation led us to wonder if 
these enzymes have critical functions that facilitate differentiation. To establish the significance of the 
BCAT2 enzyme during rat myoblast differentiation, we knocked down BCAT2 protein in myoblasts 
using reverse siRNA transfection.  Forty-eight hours after growing transfected myoblasts, the myoblasts 
were then placed in differentiation media (D0) and allowed to differentiate for five days. Cell transfected 
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with control siRNA were able to differentiate well, whereas BCAT2 knockdown cells showed no visible 
cell-to-cell fusion or myotube formation (Fig. 7A). Furthermore, BCAT2 siRNA treated wells showed a 
visible loss in cell number at D1 and D2 compared to D0 (Fig. 7A). 
 Protein levels of MHC were significantly reduced by over 80% at D3 in BCAT2-siRNA 
myoblasts (p<0.05), and there was no expression of troponin at any days in these cells (Fig. 7B and C). 
Expression of myogenin was also completed abolished by BCAT2 knockdown (Fig. 7B and C). Lastly, 
phosphorylation of S6 was significantly reduced at D2 (p<0.05) and showed a trend to be reduced at D3 
and D4 as well (Fig. 7B and C). Clearly, these results demonstrate that BCAT2 serves an essential role in 
the differentiation of rat myoblasts.  
 
BCKD disruption prevents L6 myoblast differentiation 
 We next observed the effect of disrupting the BCKD subunit BCKDE1α in rat myoblasts. 
Similarly to the previous experiment, we reverse transfected myoblasts with BCKDE1α siRNA, then 
placed these cells in differentiation media 48 hours later. The results of this experiment are similar to 
those seen in BCAT2 knockdown. Control transfected cells robustly fused to form healthy myotubes, 
whereas BCKD knockdown cells showed no visible fusion or myotube formation (Fig. 8A). Also similar 
to BCAT2 knockdown cells, BCKDE1α disrupted cells showed a visible reduction in cell number at D1 
and D2 compared to D0 (Fig. 8A).  
Levels of troponin were also completely abolished in BCKDE1α knocked-down cells, while 
levels of MHC were significantly reduced by over 90% by D4 (p<0.05) (Fig. 8B and C). Myogenin 
levels were also almost completely abolished by BCKDE1α knockdown, and ph-S6 levels were 
significantly reduced by ~20% at D2 of differentiation (p<0.05) (Fig. 8B and C). Thus, similar to 
BCAT2, adequate BCKD function is essential to myoblast differentiation. 
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BCAT2 and BCKDE1α siRNA transfection reduces cell viability 
 To quantify the portion of living and/or viable cells in BCAT2 and BCKDE1α knockdowns, we 
performed a cell viability assay. Myoblasts transfected with two different BCAT2 targeting siRNA 
oligonucleotides both resulted in a reductions in cell viability at D1 and D2, where myoblasts treated with 
BCAT2 siRNA-1 at D2 showed significant reductions (p<0.05) (Fig. 9A). Similarly, myoblasts 
transfected with two different BCKDE1α targeting siRNA oligonucleotides also both showed a 
significant reduction in cell viability at D1 and D2 (p<0.05) (Fig. 9B). These results demonstrate that 
knockdown of BCAT2 or BCKDE1α result in a reduction in the number of healthy viable cells, which 
confirms what we visually observed in Figure 7A and 8A. Conclusively, disruption of these enzymes 
impairs myoblast proliferation and survival. From this figure onward, we attempt to determine the 
mechanism by which BCAT2 disrupted cells do not differentiate. We focused on BCAT2 as it is the first 
step of BCAA catabolism, and has additional regulatory functions in conjunction with BCAA catabolism 
such as glutamine/α-ketoglutarate production.  
 
Increasing the cell confluency does not rescue differentiation of BCAT2 disrupted myoblasts 
 We next sought to determine if we could rescue the differentiation of BCAT2 disrupted 
myoblasts by adding a greater number of viable cells after transfection. Since BCAT2 knockdown 
resulted in a loss of viable cells at D1 and D2 (Fig. 7A & 9A), we wondered if the lack of myoblast fusion 
and differentiation was due to a lack of cell confluency. To address this question, 24 hours post-
transfection we combined three wells worth of BCAT2 deficient cells into one new well (Fig. 10A). To 
control transfected cells, we did not combine wells but we similarly trypsinized them and also transferred 
them to new wells (Fig. 10A). After another 24 hours, we placed these cells in differentiation media (D0).   
 As expected, increasing the number of cells increased the cell confluency at D1 of differentiation, 
as there were minimal empty spaces between cells in the BCAT2 siRNA condition (Fig. 10B). However, 
despite there being more cells, BCAT2 disrupted cells still showed an absence of differentiation and 
 57 
exhibited a marked reduction in cell number at D3 of differentiation (Fig. 10B). In conclusion, these 
findings suggest that the reason BCAT2 deficient myoblasts do not fuse and differentiate is not due to 
there being a lack of adherent cells.  
 
Supplementing BCKAs to BCAT2 disrupted myoblasts does not rescue myoblast differentiation 
 To determine an alternate reason as to why BCAT2 disrupted myoblasts do not differentiate, we 
wondered if it was due to BCAT2-mediated production of branched-chain α-keto acids (BCKAs) being 
disrupted (Fig. 3). Thus, we tried to determine if supplementing BCKAs to BCAT2 deficient myoblasts 
could rescue their differentiation. Supplementing the BCKAs KIC, KMV, and KIV (BCKAs of leucine, 
isoleucine, and valine, respectively) to BCAT2 siRNA treated cells resulted in no visible amelioration of 
myoblast fusion or cell death (Fig. 11A). Supplementation of BCKAs to BCAT2 disrupted cells also did 
not rescue the attenuation of myogenic proteins (MHC-1, troponin, myogenin) or mTORC1 signaling (ph-
S6) (Fig. 11B). Hence, the reason BCAT2 disruption negatively affects myoblast differentiation is likely 
due to another BCAT2-mediated function other than BCKA production.  
 
BCAT2 disruption induces programmed cell death in myoblasts 
 To determine a mechanism by which BCAT2 disruption affects cell survival and differentiation, 
we wondered if these cells became apoptotic in response to BCAT2 knockdown. Thus, we probed for 
caspase-3 protein, which when cleaved, induces programmed cell death via apoptosis. We observed that 
BCAT2 knockdown significantly increased the amount of cleaved caspase-3 at D1 of differentiation 
(p<0.05) (Fig. 12). Additionally, supplementing BCKAs to BCAT2 disrupted myoblasts did not rescue 
levels of cleaved caspase-3 (Fig. 12). Thus, these findings demonstrate that BCAT2 disrupted myoblasts 
become apoptotic when they attempt to differentiate.  
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FIGURE 4. The leucine metabolite KIC can regulate L6 myoblast differentiation 
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Figure 4. A) L6 rat myoblasts were differentiated in either differentiation media (DM) with all amino 
acids (CTR), DM without L- alanine, DM without L-leucine, or DM without L-leucine supplemented 
with 200µM KIC for a period of 5 days. Day 0 (D0) represents the moment immediately before being 
shifting the cells to differentiation media, and day 5 (D5) represents the moment after allowing the cells 
to differentiate for five days. Leucine deprived cells showed an inability to differentiate, as indicated by 
the absence of myotube formation. Supplementing KIC to leucine deprived cells was able to rescue 
myotube formation. B) Cells were harvested on day 0 (D0) and day 5 (D5) and probed for myosin 
heavy chain-1 (MHC-1), troponin, & myogenin, which are markers of differentiation. The absence of 
leucine impaired the expression of these proteins after 5 days of differentiation. However, 
supplementing the leucine-deprived differentiation medium with KIC was able to rescue levels of 
MHC-1, myogenin, and troponin. * denotes significantly different compared to all other conditions in 
the D5 group (p<0.05). C) mTORC1 signaling was attenuated by leucine deprivation, but rescued by 
KIC supplementation. * denotes significantly different compared to all other conditions in the D5 group 
(p<0.05). n = 3, with 2 replicates per treatment. Data are mean ± SEM. 
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FIGURE 5. Expression of BCAA catabolic enzymes BCAT2 and BCKD increase during L6 
differentiation 
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FIGURE 6. Intracellular BCAA concentrations do not change during L6 myoblast differentiation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. A) BCAT2 (branched-chain aminotransferase-2) and BCKDE1α (branched-chain alpha-
keto dehydrogenase E1α) protein expression during a 5-day differentiation of L6 myoblasts. BCAT2 
levels showed a non-significant trend to increase to day 3 of differentiation (D3). BCKDE1α showed 
a consistent increase on each day of differentiation, where day 4 (D4) and day 5 (D5) were 
significantly greater than day 1 (D1) (p<0.05). B) BCAT2 mRNA and BCKDE1α mRNA expressed 
relative to HPRT control mRNA over a 5 day differentiation of L6. BCAT2 showed non-significant 
increases at D1 and D4, whereas BCKDE1α showed significant elevation on D2 compared to D5 
(p<0.05). n = 3, with 2-3 replicates per treatment. Data are mean ± SEM. 
 
Day of differentiation 
Figure 6.  Intracellular BCAA concentration at each day of differentiation was measured using a 
fluorometric assay. Values were corrected using sample protein concentration. No significant change 
in intracellular BCAA concentrations was observed during differentiation. n = 3, with 3 replicates 
per treatment. Data are mean ± SEM. 
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FIGURE 7. BCAT2 disruption prevents L6 myoblast differentiation 
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BCAT2 siRNA: 
           D0     D1     D2     D3     D4     D5  
    -    +  -    +   -   +   -   +   -    +   -   + BCAT2 siRNA: 
           D0     D1     D2     D3     D4     D5  
     -    +  -    +   -   +   -    +   -   +   -   + 
BCAT2 siRNA: 
           D0     D1     D2     D3     D4     D5  
     -    +   -   +   -    +   -   +   -    +   -   + 
BCAT2 siRNA: 
           D0     D1     D2     D3     D4     D5  
     -    +   -   +   -    +   -    +  -    +   -   + BCAT2 siRNA: 
           D0     D1     D2     D3     D4     D5  
     -   +   -   +    -   +   -   +   -    +   -   + 
Figure 7. A) L6 rat myoblasts were transfected with BCAT2 siRNA, or control (CTR) siRNA. Myoblasts 
transfected with BCAT2 siRNA showed no ability to differentiate over 5 days, as indicated by the absence 
of myotube formation. A visible loss in cell number was also observed at D1 and D2. B) Cells were 
harvested and probed for myogenic proteins MHC-1, troponin, and myogenin. The expression of 
myogenic proteins was severely attenuated by BCAT2 knockdown. mTORC1 signaling was also impaired 
by BCAT2 knockdown. * with bar denotes significantly different (p<0.05). n = 3, with 2 replicates per 
treatment. Data are mean ± SEM. 
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FIGURE 8. BCKD disruption prevents L6 myoblast differentiation 
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Figure 8. A) L6 rat myoblasts were transfected with BCKDE1α siRNA, or control (CTR) siRNA. 
Myoblasts transfected with BCKDE1α siRNA showed no ability to differentiate over 5 days, as indicated 
by absent myotube formation. A visible loss in cell number was also observed at D1 and D2. B) Cells 
were harvested and probed for myogenic proteins MHC-1, troponin, and myogenin. The expression of 
myogenic proteins was severely attenuated by BCKDE1α knockdown. mTORC1 signaling was also 
impaired by BCKDE1α knockdown. * with bar denotes significantly different (p<0.05). n = 3, with 2 
replicates per treatment. Data are mean ± SEM. 
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FIGURE 9. BCAT2 and BCKDE1α siRNA transfection reduces cell viability 
A)  
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Figure 9. A) Cell viability was measured in wells transfected with two different BCAT2 siRNA 
oligonucleotides. Both siRNA oligos induced reduced cell viability in treatment wells at day 1 (D1) and 
day 2 (D2) of differentiation compared to control transfected wells. B) Cell viability was measured in 
wells transfected with two different BCKDE1α siRNA oligonucleotides. Both siRNA oligos induced 
reduced cell viability in treatment wells also at D1 and D2 compared to control transfected myoblasts. * 
with bar denotes significantly different (p<0.05). n = 3, with 2 replicates per treatment. Data are mean ± 
SEM. 
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FIGURE 10. Increasing the cell confluency does not rescue differentiation of BCAT2 disrupted 
myoblasts 
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FIGURE 11. Supplementing BCKAs to BCAT2 disrupted myoblasts does not rescue myoblast 
differentiation 
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Figure 10. Increasing the cell confluency does not rescue differentiation of BCAT2 disrupted myoblasts 
A) 24 hours after being transfected, cells from 3 BCAT2 transfected wells were combined into one new 
well. Cells from one control well were also moved into one new well. Twenty-four hours after wells were 
combined, the cells were shifted to differentiation media. B) Increasing the cell number did not rescue 
myoblast differentiation by day 5 (D5), as absent myotube formation and a loss in cell number was still 
observed by D3 of differentiation. Number of experiments = 2.  
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Figure 11. To determine if supplementing BCAT2 siRNA transfected myoblasts with BCKAs could 
rescue their differentiation, transfected myoblasts were supplemented with 200µM α-ketoisocaproate 
(KIC), 200µM α-ketomethylvalerate (KMV), and 200µM α-ketoisovalerate (KIV). A) Adding BCKAs did 
not rescue myoblast differentiation, as the absence of myotube formation and a loss in cell number was 
still observed. B) Expression of myogenic proteins MHC-1, troponin, and myogenin, and mTORC1 
signaling, were not rescued by BCKA supplementation. BCATi = BCAT2 siRNA. * with bar denotes 
significantly different (p<0.05). n = 3, with 2 replicates per treatment. Data are mean ± SEM. 
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FIGURE 12. BCAT2 disruption induces programmed cell death in myoblasts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D0 D1 D2 D3 D4 D5 
CT
R 
si
RN
A 
BC
AT
2i
 
BC
AT
2i
 +
 K
IC
/K
M
V/
KI
V 
CT
R 
si
RN
A 
BC
AT
2i
 
BC
AT
2i
 +
 K
IC
/K
M
V/
KI
V 
CT
R 
si
RN
A 
BC
AT
2i
 
BC
AT
2i
 +
 K
IC
/K
M
V/
KI
V 
CT
R 
si
RN
A 
BC
AT
2i
 
BC
AT
2i
 +
 K
IC
/K
M
V/
KI
V 
CT
R 
si
RN
A 
BC
AT
2i
 
BC
AT
2i
 +
 K
IC
/K
M
V/
KI
V 
CT
R 
si
RN
A 
BC
AT
2i
 
BC
AT
2i
 +
 K
IC
/K
M
V/
KI
V 
Cleaved caspase-3 
~15 kDa 
Caspase-3 
~30 kDa 
Figure 12. BCAT2 transfected myoblasts show increased apoptotic signaling as indicated by increases in 
caspase-3 cleavage at day 1 (D1) of differentiation. Addition of 200µM α-ketoisocaproate (KIC), 200µM 
α-ketomethylvalerate (KMV), and 200µM α-ketoisovalerate (KIV) to BCAT2 transfected cells did not 
rescue increased apoptotic signaling in myoblasts. BCATi = BCAT2 siRNA. * with bar denotes 
significantly different (p<0.05). n = 2, with 2 replicates per treatment. Data are mean ± SEM. 
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DISCUSSION 
 In this study, we show that the leucine metabolite KIC can positively regulate rat 
myoblast differentiation, even in the absence of leucine. This was evident as myotube formation, 
along with levels of myogenic proteins, were rescued in leucine-deprived-KIC-supplemented 
cells. Additionally, we observed that mTORC1 signaling was absent in leucine-deprived cells, 
but was ameliorated in leucine-deprived-KIC-supplemented cells. Our work has also shown that 
BCAT2 and BCKDE1α protein levels increase during rat myoblast differentiation. Although the 
pattern of mRNA expression does not follow the pattern of protein expression, levels of BCAT2 
and BCKDE1α mRNA also increase at certain points of differentiation.  Most interestingly, in 
our study we found that the disruption of BCAT2 or BCKDE1α in rat myoblasts abolishes their 
ability to differentiate and BCAT2 disruption induces programmed cell death. This was evident 
based on the finding that myoblasts from both BCAT2 and BCKDE1α knockdown did not show 
any visible myotube differentiation and had lower amounts of adherent cells and reduced cell 
viability at D1 and D2. BCAT2 deficient myoblasts also showed increased caspase-3 cleavage 
also at D1 and D2. Knockdown of either BCAT2 or BCKDE1α also abolished expression of 
myogenic proteins and mTORC1 signaling. Lastly, the essentiality of BCAT2 to rat myoblast 
differentiation is not due to its role in synthesizing BCKAs, as supplementing BCKAs to BCAT2 
deficient myoblasts did not rescue their differentiation or apoptotic signaling.  
 Previous literature has shown that the leucine metabolites KIC and HMB can positively 
regulate skeletal muscle hypertrophy in animals and humans [8]–[13], while HMB has also been 
shown to positively regulate the differentiation of mammal skeletal muscle myoblasts as well 
[14]. However, KIC has not been shown to regulate the differentiation of skeletal muscle 
myoblasts to date. Our study demonstrates that indeed KIC can positively regulate skeletal 
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muscle myoblast differentiation, even in the absence of leucine (Fig. 4). Although, the 
mechanism by which KIC can rescue differentiation likely lies within the ability of the cell to 
convert KIC back to leucine via the BCAT2 enzyme. Leucine is an essential amino acid, thus, 
protein synthesis and cell growth cannot continue in leucine-deprived cells, as was also 
demonstrated by Averous et al. 2012 [6]. The addition of KIC to the cells likely allows them to 
reversibly transaminate KIC back to leucine, allowing differentiation to occur.  
In our experiments, the addition of KIC also restored mTORC1 signaling as indicated by 
levels of phosphorylated S6 protein (Fig. 4C). Although mTORC1 signaling may be considered 
inhibitory to myoblast differentiation due to disruption of the IRS/PI3K/AKT pathway [121], 
mTORC1 signaling is still activated by leucine stimulation in myoblasts [207]. The level of S6 
phosphorylation was also similar to that seen in cells cultured in control (leucine-containing) 
medium. This suggests that indeed KIC supplementation can rescue amino acid nutrient status in 
the cell in cases of leucine-deprivation.  
 The expression levels BCAT2 and BCKD have also never been elucidated in a time-
dependent manner during myoblast differentiation. Our experiments show that levels of both 
these enzymes appear to increase during differentiation, with BCKD especially showing a robust 
significant increase in expression over the five-day differentiation period (Fig. 5A). This result 
also suggests that BCAA oxidation may be increased during differentiation, although this cannot 
be said without some uncertainty, as we did not measure enzymatic activity. mRNA expression 
of these proteins also showed increased levels at earlier stages of differentiation (Fig. 5B), 
indicating there is an upregulation in the transcription of BCAA catabolic enzymes in response to 
differentiation. It would be interesting to know if any of the transcriptional myogenic regulatory 
factors, such as MyoD, can mediate this upregulation.  
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Because we saw an increase in catabolic enzyme expression, we also wondered if there 
were corresponding changes in intracellular BCAA levels. Our experiments did not find any 
significant change in intracellular BCAA levels over the five-day differentiation period (Fig. 6). 
It should be noted that our variability between replicate experiments was quite high, yielding a 
large SEM in each group. Thus, further investigation is required to confirm this result. However, 
if this result is accurate, then it suggests that levels of BCAA remain constant in the cell, even 
though they may be increasingly catabolized. This suggests transport of BCAAs into the cell 
may also increase during differentiation to replenish BCAAs catabolized by BCAT2/BCKD. 
This theory is supported by findings by Moran et al. 2002 [208], who have shown that 
transcription of amino acid transporters increases during mouse myoblast differentiation. 
To establish the importance of BCAA catabolism to rat myoblast differentiation, we 
disrupted both BCAT2 and BCKDE1α, and observed a severe impairment in myoblast 
differentiation (Fig. 7 & 8). Not only did these cells not differentiate, but BCAT2 knockdown 
cells also had increased apoptotic signaling, and both BCAT2 and BKCDE1α knockdown cells 
resulted in visible cell death/loss around D1 and D2.  The amelioration of cell death after D1 and 
D2 was likely due to the effect of siRNA treatment subsiding, as after D3 protein levels of both 
BCAT2 and BCKDE1α in knockdowns start to return (Fig. 7B & 8B). Adding more cells to 
knockdown treatments also did not rescue myoblast fusion, as we still observed reduced cell 
number (Fig. 10). Thus, the disruption of either of these enzymes in rat myoblasts induces severe 
detrimental effects that impair myoblast survival, proliferation, and differentiation. 
BCAT2 and BCKDE1α knockdown also impaired mTORC1 signaling, as indicated by 
lower levels of phosphorylated S6 protein (Fig. 7B & 8B). The role of mTORC1 signaling in 
myoblast differentiation is controversial, as studies suggest that increased mTORC1 signaling is 
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a positive regulator of skeletal muscle hypertrophy [109], but a negative regulator of myoblast 
differentiation [121]. We find that mTORC1 signaling is reduced in BCAT2 and BCKDE1α 
knockdown cells, suggesting that mTORC1 signaling is likely not responsible for disrupting the 
differentiation of these myoblasts. These results contradict those reported by She et al. 2007 
[198], as they found BCAT2 knockdown mice had elevated levels of mTORC1 signaling in 
muscle tissue. Additionally, they attributed the increase in mTORC1 signaling to elevated 
plasma BCAAs caused by BCAT2 disruption. We cannot explain the difference in mTORC1 
signaling between their model of existing muscle tissue and our model muscle differentiation. 
However, these results confirm the role of mTORC1 is ambiguous and likely inconsistent when 
comparing the regulation of muscle differentiation to the regulation of developed muscle tissue. 
Why are these enzymes that mediate BCAA catabolism so important to myoblast 
differentiation? As discussed in the literature review section of this thesis, BCAT2 serves as first 
enzyme that catabolizes BCAAs to produce corresponding α-keto acids (BCKAs), which can be 
further metabolized by the BCKD complex. BCAT2 also simultaneously reversibly aminates α-
ketoglutarate to produce glutamate, which can then be used for glutamine synthesis. To test 
whether BCAT2 deficient myoblasts did not differentiate due to disrupted BCKA production, we 
supplemented these BCAT2 deficient myoblasts with BCKAs (Fig. 11). However, BCKA 
supplementation did not rescue myoblast differentiation, myogenic protein expression, or 
apoptotic signaling (Fig. 11 & 12). This suggests that the importance of BCAT2 to rat myoblast 
differentiation is not due to its role in producing the BCKAs KIC, KMV, KIV, although we 
cannot rule this out completely as BCKA production may be required in conjunction with some 
other BCAT2-mediated process. The finding that BCKAs could not rescue differentiation was 
surprising, as there is convincing evidence that BCKAs, particularly KIC, can regulate many 
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aspects of skeletal muscle anabolism and muscle differentiation as described earlier. If it is not 
BCKAs themselves which promote anabolic mechanisms during differentiation, then it is 
possible that BCKAs facilitate other BCAT2-mediated reactions which are responsible for 
inducing anabolism. Conclusively, BCKA production may not be the major anabolic component 
of BCAA catabolism.  
Since BCKA production was ruled out, another possibility is the role of BCAT2 in the 
glutamine/alanine cycle. BCAT2 can use BCAAs to make glutamate, or conversely, it can use 
BCKAs to produce α-ketoglutarate (Fig. 2). In separate reactions, glutamate can also be a 
substrate to produce alanine via the alanine transaminase enzyme, or be converted to glutamine 
via glutamine synthetase (Fig. 2). She et al. 2010 [15] demonstrated that BCAT2 knockout mice 
have 43-79% declines in muscle concentration of alanine, glutamate, and glutamine. Glutamine 
is an important precursor for nucleotide synthesis [209], and can positively regulate protein 
turnover [210]. Alanine is an important gluconeogenic substrate [211]. However, the lack of 
myoblast differentiation is likely not due to alanine deficiency as in our study we showed that 
alanine deprivation did not affect differentiation (Fig. 4). Thus, it is possible BCAT2 disrupted 
cells do not differentiate due to reduced intracellular glutamine formation. Glutamine has also 
been shown to be responsible for mTORC1 activation [3], and reduced levels of glutamine may 
explain why we observed lower mTORC1 signaling in BCAT2/BCKDE1α knockdowns. 
However, it should be noted that the differentiation media myoblasts are cultured in already 
contains 292 mg/L of L-glutamine, although this may not be enough to rescue glutamine 
deficiency and/or not enough of it can enter the cell.  
There is also a possibility that glutamate and α-ketoglutarate, which can both be 
interchangeably produced by BCAT2 and alanine transaminase, become limiting in BCAT2 
 78 
knockdown cells (Fig. 2). α-ketoglutarate production from glutamate has been shown to be a 
major anaplerotic reaction during exercise which causes expansion of the TCA cycle 
intermediate pool [212]. Thus, BCAT2-mediated α-ketoglutarate production may contribute to 
adequate regulation of the TCA cycle and energy homeostasis. However, this may still not 
explain why BCAT2 deficient myoblast did not differentiate. This is because the differentiation 
media also contains 75 mg/L L-glutamic acid (glutamate), and even though BCAT2 is not 
available to convert glutamate to α-ketoglutarate, alanine transaminase was not disrupted and 
thus should still be able to produce α-ketoglutarate from glutamate (Fig. 2). However, there 
remains a possibility that alanine transaminase alone cannot keep up with the demand of 
glutamate/α-ketoglutarate conversion required. Additionally, the amount of glutamate in the 
differentiation media may not be sufficient enough to rescue glutamate deficiency in knockdown 
cells. 
 As we observed, BCKDE1α deficient myoblasts also do not differentiate. The disruption 
of BCKDE1α activity should theoretically cause an elevation in the BCAA and BCKA 
intracellular concentrations [202]. High levels of BCAAs/BCKAs have been shown to be 
responsible for causing neuro-degeneration in patients with maple-syrup urine disease (MSUD) 
[213].  High levels of KIC have also been shown to induce apoptosis of glial and neuronal cells 
in culture [214]. Jouvet et al. 2000 [214] also showed that high doses of KIC administration 
caused impaired cellular respiration as marked by reduced oxygen consumption and 
mitochondrial death [214]. Another study also showed that the administration of leucine to 
neuronal cells that are overexpressing the BCKD kinase (thus reducing BCKD activity) results in 
cell death [16]. Hence, it is possible that the accumulation of BCKAs including KIC in 
BCKDE1α disrupted myoblasts induces similar cytotoxic effects that cause apoptosis-mediated 
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death, along with reduced proliferation, and differentiation. An alternate reason that may explain 
why BCKDE1α deficient myoblast do not differentiate is the possibility that the 
glucogenic/ketogenic substrates that are formed from BCKA oxidation are impaired. Substrates 
including isovaleryl CoA, succinyl CoA, and acetyl CoA can be produced from BCKA oxidation 
via BCKD, and can enter the TCA cycle (Fig. 3). Thus, the disruption of BCKD in myoblasts 
could theoretically cause decreased production of these substrates in myoblasts, although the 
contribution of BCKD-derived CoA substrates to anaplerosis and energy production is not 
known. Additionally, amino acid catabolism is believed to contribute only 10-15% to whole 
body energy production [215], thus it is not likely that energy production is impaired by BCKD 
disruption. However, further investigation is warranted to determine what the contribution of 
these substrates produced from BCKAs /BCAAs are to muscle energy metabolism.  
 Lastly, the increase in apoptotic signaling at D1 and D2 in BCAT2 knockdown cells 
likely explains the reduction in cell number, cell viability, and the absence of differentiation. 
Indeed, increased apoptotic signaling has been associated with cell death [214], along with the 
suppression of cell proliferation [216] and differentiation [217]. As discussed, there are a number 
of factors that may explain why disruption of these enzymes inhibits differentiation, and causes 
programmed cell death of myoblasts. However, further research is required to determine which 
factors are the likely culprits. 
   
 
 
 
 
 80 
CONCLUSION 
 In conclusion, our study shows that: 
1. The branched chain amino acid leucine is essential to myoblast differentiation. 
The leucine metabolite KIC can also promote myoblast differentiation, even 
under conditions of leucine deprivation. This result demonstrates that BCAAs 
and their corresponding metabolites have regulatory roles in differentiation.  
2. Expression of BCAA catabolic enzymes BCAT2 and BCKD increase during 
differentiation, suggesting that BCAA catabolism has an important role during 
myoblast differentiation.  
3. Disruption of BCAA catabolic enzymes BCAT2 and BCKD results in 
programmed cell death of myoblasts and impairs their ability to differentiate. 
4. The impairment of BCAT2 deficient myoblasts is not due to reduced branched-
chain α-keto acid production.  
Our study demonstrates that BCAA catabolism plays an important role in the regulation 
of skeletal muscle development.  The significance of this data is that it implicates the 
BCAA catabolic pathway as a critical regulator of skeletal muscle formation and 
regeneration. BCAT2 and BCKD are targets that are essential for skeletal muscle 
development. Thus, developing therapies that ensure the adequate function of these 
enzymes may promote skeletal muscle generation in patients with myopathic diseases. 
We also show that for individuals who have mutations in the BCAT2 protein, the intake 
of branched-chain α-keto acids likely would not ameliorate compromises in skeletal 
muscle development.  
 
 81 
FUTURE WORK 
1. Measure intracellular BCAA/BCKA concentrations in BCAT2 and BCKDE1α 
deficient cells 
The knockdown of BCAT2 should theoretically cause an accumulation of 
intracellular BCAAs leucine, isoleucine, and valine. The knockdown of BCKD 
should similarly cause an accumulation of BCKAs KIC, KMV, and KIV. 
Confirming the elevation of these substrates would support the notion that it may 
be high levels of BCAAs/BCKAs that induce cell toxicity and impair 
differentiation. 
2. Measure enzyme activity of BCAT2 and BCKD during differentiation 
We observed an increase in BCAT2 and BCKDE1α expression during myoblast 
differentiation. This result suggests there likely is an increase in BCAA 
catabolism during differentiation. To support this notion, finding an increase in 
enzyme activity would support the idea that BCAA catabolism is increased during 
differentiation.  
3. Supplement BCAT2 deficient myoblasts with exogenous L-glutamine, L-glutamate, 
and α-ketoglutarate 
The impairment of the BCAT2 enzyme should theoretically impair the production 
of intracellular glutamine, glutamate, and α-ketoglutarate. To determine if this 
impairment is what causes the disruption of BCAT2-deficient myoblast 
differentiation, we can supplement the differentiation media with these substrates 
to determine if it can rescue differentiation.  
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4. Determine the contribution of BCKA catabolism to anaplerosis 
To determine if BCKD deficient myoblasts do not differentiate due to disrupted 
energy metabolism, we would need to measure the proportion of CoA derivatives 
made from BCAAs that end up in the TCA cycle. One could do this by 
introducing [14C] labeled BCAAs into the cell culture media. Following this, you 
can then measure label flow through the TCA cycle and determine the amount of 
[14C] labeled TCA substrates that are produced, such as [14C]-succinate or [14C]-
malate.  
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DETAILED LABORATORY METHODS AND PROTOCOLS 
 
I. Cell passing and differentiation protocol 
Reagents: 
Growth medium (GM) 
AMEM (Wisent #310-010-CL) 
10% FBS (Gibco #12484-028) 
1% antibiotic (Wisent #450-201-EL) 
Differentiation medium (DM) 
AMEM (Wisent #310-010-CL) 
2% Horse serum (Gibco #26050088) 
1% antibiotic 
Phosphate buffered saline (PBS) (Wisent #311-010-CL) 
 
1. Thawing cells 
a. Retrieve a vial from the -80°C freezer 
b. Hand thaw the vial 
c. Dilute the cells in a 10 mls of growth medium in a 10-cm plate 
d. Mix the cells well by pipetting up and down and swirling the plate 
e. Put the plate in the 37°C incubator 
f. Split the cells the next day 
2. Passing cells 
a. When cells have reached ~70% confluency it is time to split (about 48 hours later) 
b. Rinse the plate with 5 mls warm PBS 
c. Add 1 ml trypsin, mix the trypsin around the plate 
d. Put the plate in the 37°C incubator for 2 mins 
e. Remove the plate, tap the bottom of the plate lightly to detach remaining cells, check the 
plate under the microscope to ensure cells have detached 
f. Quench cells with 5 mls growth medium 
g. Add 0.65-1.0 ml of cells to new plate containing 10 mls growth medium 
h. Mix well by pipetting and swirling, then keep the plate in the 37°C incubator 
3. Differentiating cells 
a. Grow the cells to 90-100% confluency 
b. Remove the growth medium, and place the cells in 10 mls of differentiation media (DM) 
for a 10 cm plate, or 2 mls for a 6 well plate 
c. Change the DM every day if possible, and every other day at least 
 
 
II. Cell harvesting/lysis protocol 
Lysis buffer formulation (in ddH20):  
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a. 1mM EDTA 
b. 2% sodium dodecyl sulfate (SDS) 
c. 25 mM Tris-HCL pH 7.5 
d. 10 µl/ml protease inhibitor (Sigma #P8340) 
e. 10 µl/ml phosphatase inhibitor (Sigma #P5726) 
f. 1 mM DTT  
 
To harvest cells:  
1. Suck out the old differentiation media 
2. Rinse the well with PBS (2 mls PBS for 6-well plate, 5 mls PBS for 10-cm plate) 
3. Add lysis buffer (75 µl for 6-well plate, 150 µl for 10-cm plate) 
4. Use a rubber policeman to spread the lysis buffer around, detach the cells, then collect the lysate 
in a corner of a well 
5. Use a syringe to repeatedly aspirate and expel the lysate, this step is crucial 
6. Place the lysate in 1-ml tube and store at -20°C 
 
III. Western blot protocol 
STEP 1: Determine the protein concentration using the Pierce™ BCA protein assay kit (Thermo #23225) 
STEP 2: Add 4x laemmli sample buffer dye to each sample 
1. Make the 4x laemmli sample buffer dye 
a. 4ml glycerol 
b. 0.8g SDS 
c. 400 µl of 1M Tris pH 8.0 
d. 400 µl of 0.5M EDTA 
e. Add ddH20 up to 8 ml 
f. 0.1 mg Bromophenol blue 
g. When ready to use, add β-mercaptoethanol in a 4 part dye: 1 part BME ratio 
2. Add the sample buffer to your samples 
a. Add the dye in a 3 part sample: 1 part dye ratio 
b. Vortex 
c. Boil the samples at 95°C for 5 mins 
d. Vortex and centrifuge  
 
STEP 3: Make the gels 
Buffers:  
1. 4X resolving buffer 
a. 181.5 Tris base 
b. 600 mL water 
c. pH to 8.8 with HCL 
d. volume up to 1 L 
e. store at 4°C 
2. Resolving acrylamide 
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a. 0.76g BIS 
b. 300 ml acryl 40 (Amresco #0132) 
c. 100 mL water 
d. Cover bottle with foil and store at 4°C 
3. 4X stacking buffer 
a. 24g Tris base 
b. 240 ml water 
c. pH to 6.8 with HCL 
d. volume up to 400 ml 
e. store at 4°C 
4. Stacking acrylamide 
a. 1.6g BIS 
b. 150 ml acryl-40 
c. 50 ml water 
d. Cover bottle with foil and store at 4°C 
5. Gel electrophoresis running buffer (10X) 
a. 120g Tris base 
b. 576 g Glycine 
c. 40g SDS 
d. Volume up to 4L 
e. When ready to use, dilute to 1X in single distilled water in a 1 part water:9 parts 10X 
buffer ratio 
6. Transfer buffer (10X) 
a. 30.3 g Tris base 
b. 144.1 g Glycine 
c. Volume to 1 liter 
d. When ready to use, dilute to 1X by mixing: 
i. 100 ml 10X stock 
ii. 700 ml single distilled water 
iii. 200 ml methanol 
7. Ponceau S stain 
a. 0.1% (w/v) Ponceau S 
b. 0.5% (w/v) glacial acetic acid 
8. Blocking buffer 
a. 5% (w/v) non-fat milk in TBST 
9. TBST 
a. 60.57g Tris Base 
b. 87.66g NaCl 
c. 10 mL Tween-20 (Amaresco #M147) 
d. Volume up to 10 L 
 
Procedure to make gels: 
1. Clean glass plates with ethanol, ddH20, and Kimwipes™ 
2. Assemble the plates into the cast assembly 
3. Pour water into the plate assembly to ensure there is no water leakage 
4. Empty out the water 
5. Mark 1cm below the glass cover plate 
6. Make the resolving buffer (refer to chart below) 
7. Pour the resolving buffer to the mark on the cover plate 
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8. Pour a layer of ddH20 on top of the resolving buffer, and let solidify for 40 mins 
9. Once solidified, pour out the excess water from the gel 
10. Make the stacking buffer (refer to chart below) 
11. Pour the stacking buffer onto the gel, to the rim 
12. Insert a well comb  
13. Let solidify for about 30 minutes 
14. After solidifying, remove the glass plate from the cast assembly, and insert the plates into the 
electrode assembly 
 
Resolving gel (for one gel) 
 10% gel 15% gel 
4X resolving 
buffer 
1.99 ml 1.99 ml 
Resolving 
acrylamide 
2.65 ml 3.98 ml 
ddH20 3.32 ml 1.99 ml 
10% APS  40 µl 40 µl 
TEMED 8 µl 8 µl 
 
Stacking gel (for one gel) 
 10% gel 15% gel 
4X stacking 
buffer 
0.66 ml 0.66 ml 
Stacking 
acrylamide 
0.432 ml 0.432 ml 
ddH20 1.882 ml 1.882 ml 
10% APS  19.8 µl 19.8 µl 
TEMED 2.6 µl 2.6 µl 
 
Loading the gels: 
1. Put the electrode assemblies into the corresponding plastic container 
2. Fill the wells up with 1X gel running buffer to ensure the gel remains moist 
3. Fill up the plastic container about halfway with running buffer 
4. Load the first well of the gel with 5 µl protein ladder (Biorad #161-0374) 
5. Load the remaining wells with your samples 
6. Fill the electrode assembly with gel running buffer to the top 
7. Place a stir bar in the running unit 
8. Run the gel initially at 60V until the samples have run through the stacking gel 
9. Run the gel at 100V until the dye front has run out of the gel 
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STEP 4: transfer the proteins to membrane 
Transferring the gels to PVDF membranes: 
1. Ensure you have enough 1X transfer solution, filter paper, and PVDF (Bio rad #162-0177) 
membranes cut 
2. Place a transfer casket in a tray full of 1X transfer buffer, ensure the red/white side is down 
3. Place one sponge soaked in buffer on the red/white side 
4. Place one filter paper soaked in buffer on top of sponge, squeegee out any air bubbles 
5. Place PVDF membrane on filter paper, squeegee out any air bubbles 
6. Remove gel from glass casket, cut off the stacking gel 
7. Place the gel on top of your membrane in the transfer casket, make sure gel is thoroughly 
drenched in transfer buffer, squeegee out any air bubbles 
8. Place a filter paper soaked in transfer buffer on top of the membrane, squeegee out any air 
bubbles 
9. Place a sponge soaked in transfer buffer on top of the filter paper, squeegee out any air bubbles 
10. Close the transfer casket securely, and place the casket into the transfer unit 
a. Make sure the white/red side is facing the positive terminal, the black side should face the 
negative terminal 
11. Place a stir bar, and run at 23V overnight 4°C. Alternatively, run for 2.5 hours at ~300 mA, 
making sure unit stays cool.  
 
STEP 5: Obtaining an image 
Immunoblotting procedure: 
1. Once the gels have transferred, remove the membranes and keep them in TBST 
2. Remove TBST, add Ponceau-S solution for 8 minutes to see protein  
3. Mark the protein ladder with a pen 
4. Cut the membrane to obtain portions you wish to blot 
5. Rinse the membranes with TBST 
6. Incubate the membranes in blocking buffer 
7. Add primary antibody (diluted in 2% (w/v) BSA in TBST) 
8. Incubate overnight at 4°C 
9. The next day, rinse 2x quickly with TBST 
10. Rinse 3X for 5 mins each with TBST 
11. Add secondary antibody (diluted 1:10,000 in blocking buffer) 
12. Incubate for 3 hours at room temp 
13. Rinse 2X quickly with TBST 
14. Rinse 3X for 5 mins each with TBST 
15. Add 1-ml of immunblot solution to membrane (500µl solution A + 500µl solution B) (Millipore 
#WBKLS0500) 
16. Incubate for approximately 1-10 minutes depending on how strong the signal usually comes out 
17. Image for luminescence using Kodak Imagestation™ 4000mm Pro 
18. Afterwards, rinse membranes with TBST and store at 4°C 
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IV. Leucine deprivation + KIC rescue experiment 
 
STEP 1: Make the differentiation media 
1. Dissolve 10.04g RPMI 1640 powder (US Biologicals R8999-03) in 800 mls ddH20 water. This 
RPMI is missing glutamine, sodium bicarbonate, alanine, and leucine.  
2. Add L-glutamine (233.6 mg) 
3. Add sodium bicarbonate (1.76 g) 
4. Adjust pH to 7.2 with HCL 
5. Aliquot the solution into the separate bottles. Then supplement with amino acids. The final 
concentration of amino acids is meant to mimic those of AMEM.  
a. BOTTLE 1 = CTR DM 
i. Add 200 mls RPMI solution 
ii. Add 10.5 mg L-leucine 
iii. Add 5 mg L-alanine 
b. BOTTLE 2 = DM w/o Alanine 
i. Add 200 mls RPMI solution 
ii. Add 10.5 mg L-leucine 
c. BOTTLE 3 = DM w/o Leucine 
i. Add 350 mls RPMI solution 
ii. Add 8.75 mg L-alanine 
6. Add the horse serum and antibiotic to each solution 
a. CTR DM 
i. 4.08 mls HS 
ii. 1 ml AB 
b. DM w/o alanine 
i. 4.08 mls HS 
ii. 1 ml AB 
c. DM w/o leucine 
i. 7.14 mls HS 
ii. 1.75 mls AB 
 
STEP 2: Prepare α-ketoisocaproate (KIC) (Sigma #K0629) 
1. Dissolve KIC in ddH20 to obtain a concentration of 25 mg/ml 
2. Filter the solution through a syringe filter to sterilize 
 
STEP 3: Make the plates 
1. Seed 150,000 cells in 6 well plates 
2. Grow to 90-100% confluency 
3. When plates are ready to be differentiated, suck out the GM, then add the respective media we 
previously made 
4. You will have two groups that use the leucine-free DM, however, you will supplement one of 
those groups with KIC 
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CTR DM DM w/o alanine DM w/o leucine 
 
DM w/o leucine 
+ KIC 
5. Add KIC to the last group to make the final concentration of KIC 200 µM in the 2 mls of leucine-
free DM 
6. Change the DM of each group every day, and supplement KIC to the last group every day 
7. Harvest the wells with regular lysis buffer 
 
 
 
V. mRNA isolation and qPCR protocol 
 
1. mRNA isolation 
a. Grow cells in 10-cm plates to 90-100% confluency 
b. Upon reaching confluency, shift the cells to DM 
c. When it is time to harvest the cells, suck out the DM, and add 1-ml of Trizol reagent (Thermo 
Fisher #15596026) to each plate 
d. Use a 23-guage syringe to spread the Trizol around the plate and to repeatedly aspirate the lysate 
e. Place the lysate in 1-ml tubes, then follow the rest of the instructions provided in the kit (Thermo-
Fisher #12183018A). 
f. Store RNA at -80°C 
 
2. Check RNA purity 
a. Dilute 5 µl of RNA in 200 µl of 10mM Tris buffer pH 7.4 (in sterile ddH20) 
b. Place solution in a cuvette and read in a DNA/RNA spectrophotometer. Record the RNA 
concentration and 260/280 numbers. 
c. The 260/280 should be > 1.8 
 
3. cDNA synthesis 
a. To synthesize cDNA, simply follow the instructions provided with the kit (Bio-Rad #1725038) 
b. You should load to same amount of RNA from different samples into each reaction. Ideally if you 
have enough RNA, you can load 7µg, but using smaller concentrations will also work well.  
c. Incubate the reaction mixture on the hot plate at 42°C for 60 mins, not 30 mins like mentioned in 
the instructions 
d. Turn up the hot plate to 85°C and let samples incubate for 5 mins 
e. Centrifuge sample tubes after synthesis, and store at -20°C 
 
4. qPCR  
a. Follow the instructions according to the kit (Bio-Rad #1725271) 
b. Use opaque white strip tubes, and clear strip caps 
c. Make 20 µl reactions for each sample with the following components:  
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  For each 20µl reaction 
Forward primer 0.75 µl  
Reverse primer 0.75 µl  
cDNA sample 2 µl  
SSOAdvanced 
SYBRgreen supermix 
10 µl 
ddH20 sterile autoclaved  6.5 µl 
 
d. Make sure strip cap is on tightly  
e. Vortex strip tubes to mix sample 
f. Centrifuge the strip tubes  
g. Run the samples in the qPCR real time machine at the following settings:  
 
Enzyme activation 95°C / 2:00 min 
Denaturation 95°C / 0:10 sec 
Annealing 60°C / 0:20 sec 
 40x cycles 
 95°C / 0:10 sec 
In .05°C increments 65°C / 0:31 sec 
95°C / 0:05 sec 
 
 
VI. Determining intracellular BCAA concentrations 
 
STEP 1: To determine intracellular BCAA concentrations, we must first harvest the cell culture sample 
with a unique lysis buffer. This lysis buffer does not contain any SDS, which would otherwise interfere 
with the enzyme leucine dehydrogenase used in the assay. 
Lysis buffer reagents 
1. Triton X-100 
2. 1.0M Tris-HCL pH 7.5 
3. 1.0M NaCl 
4. 500mM EDTA 
5. 250mM EGTA 
6. 200mM Sodium Pyrophosphate 
7. 200mM β-glycerophosphate 
8. Leupeptin hemisulfate 
9. 200mM Sodium orthovanadate 
10. PMSF 
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Final concentrations of reagents in lysis buffer 
Prepare the lysis buffer according to these final concentrations. Aliquot and store at -20°C. 
Immediately before use, add 1µg of PMSF per ml of lysis buffer. 
1. 10µl/ml Triton X-100 
2. 20mM Tris-HCL pH 7.5 
3. 150mM NaCl 
4. 1mM EDTA 
5. 1mM EGTA 
6. 2.5mM Sodium Pyrophosphate 
7. 1mM β-glycerophosphate 
8. 1µg/ml Leupeptin Hemisulfate 
9. 1mM Sodium Orthovanadate 
10. Add 1µg/ml PMSF immediately before use  
*Adjust to final volume with ddH20. 
*For Leupeptin and PMSF, first dilute the powders in ddH20 to make a stock solution. Then from the 
stock solution calculate how much you need to obtain Xµg.  
 
STEP 2: We will now harvest the sample with the prepared lysis buffer. 
1. Rinse the well TWICE with cold PBS 
2. Add 75µl of lysis buffer to the well (for 6-well plates) or 150µl of lysis buffer (for 10cm plates) 
3. Scrape the well and collect the sample in a 1-ml syringe 
4. Release the sample into a 1.5ml tube and repeatedly aspirate and expel the sample with the 
syringe to breakdown the cell lysate 
5. Store at -20°C 
STEP 3: Now we centrifuge all the samples to remove any cell debris. 
1. Centrifuge samples at 14 x g for 5 minutes 
2. Collect the supernatant and place in a new sample tube 
3. Store at -20°C for later use or at 4°C if you will use the sample in the same day 
STEP 4: BCAA assay theory. 
 This assay allows us to determine the concentration of all BCAAs in our sample. This assay relies 
on an enzyme known as Leucine dehydrogenase (LDH). LDH is able to catabolize leucine, valine, or 
isoleucine according to the following reaction:  
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 After mixing our sample with LDH and NAD+, we can measure the amount of NADH produced 
by measuring absorbance at 340nM. After measuring the amount of absorbance, we can determine the 
amount of BCAA in the sample using a standard curve.   
 Since the amount of BCAAs in our sample is relatively small, instead of measuring absorbance 
we used fluorescence which is a more sensitive procedure. NADH absorbs light of wavelength 340±30 
nM and emits fluorescence at 460±50 nM. 
STEP 4a: Prepare the following buffers in ddH20. Buffers must be made fresh on the day of the assay. 
Store all buffers at 4°C. 
Reagents 
1. KH2PO4  
2. Na2HPO4 
3. Bovine Serum Albumin (BSA) 
4. Na2CO3 
5. K2HPO4 
6. EDTA 
7. β-mercaptoethanol 
 
Buffers 
1. 0.01M  KH2PO4  pH 6.0 (for dilution of stock BCAA standards) 
a. Dissolve 0.136g in ~95mls ddH20 
b. Adjust to pH 6.0 with KOH 
c. Adjust volume to 100mls with ddH20 
2. 25mM  Na2HPO4 pH 7.2 w/ 1mg/ml BSA (for dilution of leucine dehydrogenase) 
a. Dissolve .445 grams in ~95mls ddH20 
b. Adjust to pH 7.2 with HCL 
c. Adjust volume to 100mls with ddH20 
d. Take 20mls of this solution and put into a separate tube. Add 1mg/ml BSA to the 20mls 
(20mg BSA).  
3. 0.1M  Na2CO3 pH 10.7 (for dilution of β-NAD+) 
a. Dissolve .529g in ~45mls ddH20 
b. Adjust to pH 10.7 with HCL 
c. Adjust volume to 50mls with ddH20 
4. 0.1M  K2HPO4 pH 8.4 + 2mM EDTA + 0.02% β-mercaptoethanol (known as the “assay 
buffer”) 
a. Dissolve 3.45g K2HPO4 in ~190mls ddH20 
b. Add .148g EDTA powder 
c. Add 40µl β-mercaptoethanol 
d. Adjust to pH 8.4 with HCL 
e. Adjust volume to 200mls with ddH20 
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STEP 4b: Make the stock solution of standards. This only needs to be done when you run out of stock 
1mM standards in the freezer to use in your assay.  
1. Prepare a 1mM solution of leucine powder diluted in buffer 1: 0.01M KH2PO4  pH 6.0 
2. Aliquot into tubes containing 1ml each of this solution 
3. Store at -20°C for use in future assays 
4. Each time you perform the assay you will require 1 aliquot of the stock standard 
STEP 4c: Prepare the 96-well plate. 
1. Obtain a black opaque 96-well plate  
2. Clean the plate well with ethanol and dH20 
3. Ensure all wells are completely dry 
STEP 4d: Preparation of standard solutions. The standards must be made fresh every time you perform 
the assay. 
1. Obtain 1 aliquot of the 1mM leucine standard 
2. Thaw the tube and dilute the 1ml of leucine standard with 1ml of assay buffer (buffer 4) thus 
giving you a 500µM solution of leucine 
3. Now we need to prepare the following additional standards for the assay: 0µM, 100µM, 200µM, 
300µM, 400µM at a volume of 500µl each 
 Assay Buffer 500µM leucine 
0µM standard 500 µl 0 µl 
100µM standard 400 µl 100 µl 
200µM standard 300 µl 200 µl 
300µM standard 200 µl 300 µl 
400µM standard 100 µl 400 µl 
4. Keep the standards at 4°C until you are ready to pipette them into the wells. You should use the 
standards as soon as possible, ideally within 30 minutes. 
STEP 4e: Prepare 120 mM β-NAD+. 
Reagents 
β-NAD+ (Sigma Aldrich) 
1. To obtain a 120 mM solution, dissolve 79.611mg of β-NAD+ powder in 920.4µl of buffer 3: 0.1M  
Na2CO3 pH 10.7 
2. Vortex well and immediately place this solution on ice 
3. This solution degrades quite quickly and should be used within 30 minutes. 
STEP 4f: Prepare leucine dehydrogenase (LDH). 
Reagents 
Leucine dehydrogenase (Calbiochem) 
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1. We need to add 10µl of diluted LDH to each well. Calculate how many wells you have [(# of 
standards + # of samples) x 2 replicates]. For 20 wells you need 200µl of diluted LDH. You 
should also make extra as you likely will not be exact in pipetting. Therefore for 20 wells make 
~230ul.  
2. Once you know how much diluted LDH you need, you can prepare the solution by diluting the 
stock LDH in buffer 2: 25mM  Na2HPO4 pH 7.2 w/ 1mg/ml BSA. The final concentration of 
diluted LDH must be 7.857 Units/ml. 
3. Immediately place the diluted solution on ice. This solution should also be used within 30 
minutes. 
STEP 4g: Add reagents to the wells. 
1. Place the 96-well plate on ice 
2. To each well add: 
a. 265µl assay buffer (buffer 4) 
b. 10µl of β-NAD+ solution (step 4e) 
c. 14.2µl of sample or 14.2µl of standard 
3. Pipette the wells up and down at each step to thoroughly mix 
4. Ensure that no air bubbles enter the well by not pushing the pipette all the way down (it is okay if 
there is a tiny bit left in the tip). Air bubbles will give false readings.  
STEP 4f: Take a blank reading. 
Materials 
Biotek Synergy HT plate reader 
1. Set the fluorometer to read at 340 excitation/460 emission with a sensitivity of 80 
2. Take a reading of the plate 
3. Make sure once the reading is done to immediately place the plate back on ice 
STEP 4g: Add cold diluted LDH. 
1. Add 10µl of diluted LDH (step 4f) to each well 
2. Pipette the wells up and down to thoroughly mix 
3. Ensure that no air bubbles enter the well.  
STEP 4h: Take another reading. 
1. Set the fluorometer to read at 340 excitation/460 emission with a sensitivity of 80 
2. Take a reading of the plate 
3. Make sure once the reading is done to immediately place the plate back on ice 
STEP 4i: Incubate the plate. 
1. Incubate the plate at 37°C for 15 minutes 
STEP 4j: Take a final reading. 
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1. Set the fluorometer to read at 340 excitation/460 emission with a sensitivity of 80 
2. Take a reading of the plate 
STEP 4k: Interpret the numbers. 
 Now that you have your data, you need to subtract the second reading with cold LDH from the 
final 37°C reading for each sample/standard. The data from the first reading can be discarded. The first 
reading is only necessary because I believe it helps get the machine to give better numbers on subsequent 
readings. 
 You can now generate a standard curve with the subtracted fluorescence values you obtained 
from your standards. Following this, generate an equation for the line of best fit.  
 Using the equation for your line of best fit, go to the subtracted fluorescence values you obtained 
for your samples and plug them in to your equation to obtain the concentration of BCAAs. 
Equation of the line: y = mx + b, where y=fluorescence value and x=BCAA concentration 
 Lastly, you need to correct the BCAA concentration by the concentration of protein in the sample 
as determined by performing a Bradford assay.  
Important notes 
 This assay should be carried out without much pause. As soon as you add the cold enzyme to the 
wells the reaction will have already started (the ice is meant to slow it down). Ideally you would want to 
add the enzyme to every well simultaneously. However, if you do not have an instrument to do this you 
can add it one well at a time in a quick manner.  
 With that being said, I would not recommend trying to run many samples on one plate as it will 
take too long to add the enzyme to all wells it and may distort your readings. I recommend not running 
more than 12 samples per assay. 
 Another thing to keep in mind is you absolutely do not want any air bubbles in the well. To avoid 
this, do not completely press down on the pipette when you expel any liquid into the well. It is okay to 
have a little bit left in the tip.  
 
VII. siRNA transfection protocol 
 
1. Prepare cells 
a. Grow cells in 10-cm plates, you need 1 plate for every 6-well plate you need to make 
b. Trypsinize, centrifuge, and re-suspend cells in 0.8ml GM/10-cm plate used 
c. Count cells using a hemocytometer (use 10 µl of cells) 
d. Keep the cell solution on ice while you prepare your transfection reagents 
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2. Make transfection mixtures according to the product instructions, use the following volumes of 
siRNA, lipofectamine, and optimem.  
 
 Lipofectamine + 
optimem  
Target siRNA + 
optimem 
SCR siRNA + optimem 
BCAT2 
transfection 
5 µl lipo/well 
120 µl optimem/well 
2 µl siRNA/well 
123 µl optimem/well 
2 µl siRNA/well 
123 µl optimem/well 
BCKDE1α 
transfection 
7 µl lipo/well 
118 µl optimem/well 
3 µl siRNA/well 
122 µl optimem/well 
3 µl siRNA/well 
122 µl optimem/well 
 
3. After making the transfection mixtures, complete the following:  
a. Add 1-ml of GM that contains no antibiotic to each well of the new 6-well plate 
b. Add 250 µl of the siRNA mix (Lipo mix + siRNA mix) to each well 
c. Add 250,000 cells/well 
d. Mix thoroughly by pipetting up and down with 1-ml tip 
e. Place in 37°C incubator  
f. 24 hours later, add 1-ml regular GM that contains antibiotic 
g. After another 24 hours, suck out the GM and add 2-mls of DM 
h. Harvest with 75 µl lysis buffer, and change your DM every day 
i. Store the samples at -20°C 
 
VIII. Cell viability assay 
Reagent: Cell Counting Kit-8 (CCK-8) (Sigma #96992) 
1. Follow a similar protocol as described in the previous section “siRNA transfection protocol” 
a. Grow cells in 10-cm plates, you need 2 plates for every 96-well plate you need to make 
b. Trypsinize, centrifuge, and re-suspend cells in 0.8ml GM/10-cm plate used 
c. Count cells using a hemocytometer (use 10 µl of cells) 
d. Keep the cell solution on ice while you prepare you transfection reagents 
 
2. Make transfection mixtures according to the product instructions; use the following 
volumes of siRNA, lipofectamine, and optimem. Because the wells in a 96-well plate are 30x 
smaller than a 6-well plate, all the reagent volumes are simply divided by 30.  
 Lipofectamine + 
optimem  
Target siRNA + 
optimem 
SCR siRNA + optimem 
BCAT2 
transfection 
0.16 µl lipo/well 
4 µl optimem/well 
0.07 µl siRNA/well 
4.1 µl optimem/well 
0.07 µl siRNA/well 
4.1 µl optimem/well 
BCKDE1α 
transfection 
0.23 µl lipo/well 
3.93 µl optimem/well 
0.1 µl siRNA/well 
4.06 µl optimem/well 
0.1 µl siRNA/well 
4.06 µl optimem/well 
 
3. After making the transfection mixtures, complete the following:  
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a. Add 50 µl of GM that contains no antibiotic to each well of the new 96-well plate 
i. Ensure you make extra wells for non-transfected cells that will just differentiate 
in regular DM (this serves as the control to be used in the formula below) 
b. Add 8.3 µl of the siRNA mix (Lipo mix + siRNA mix) to each well 
c. Add 8000 cells/well 
d. Mix thoroughly by pipetting up and down  
e. Place in 37°C incubator  
f. 24 hours later, add 50 µl regular GM that contains antibiotic 
g. After another 24 hours, suck out the GM and add 100 µl of DM 
 
4. Add CCK-8 reagent 
a. After adding 100 µl of DM, add 10 µl of CCK-8 reagent  
b. Incubate at 37°C for 2 hours 
c. Read the plate at 450 nm using a spectrophotometer 
d. To get the relative cell viability use this formula 
i. Relative cell viability = (absorbance of transfected cells)/ (absorbance of cells in 
regular DM) 
e. Repeat this process every subsequent day on a different set of wells to get the relative cell 
viability for each day 
Note* although this reagent is not very toxic to cells, it is best to make duplicate wells for 
each day of differentiation, and not reuse wells to measure cell viability. 
 
VIIII. Increasing number of cells after siRNA transfection protocol 
 
1. Conduct siRNA transfection in 6-well plates as described in “siRNA transfection protocol” 
2. 24 hours after letting the cells grow in 1-ml of GM w/o antibiotic, suck out the GM, rinse with 2 
mls PBS, then add 0.5 mls trypsin to the wells 
3. Combine all the target siRNA cells into a new 50 ml tube, and combine all the control siRNA 
cells into a new 50 ml tube 
4. Centrifuge the cells of both tubes at 2000 rpm for 5 minutes 
5. Suck out the supernatant, and re-suspend the cells in 2mls GM per new well. For example, if you 
are re-seeding the cells in 15 new wells, suspend the cells in 30 mls GM. Mix the cells thoroughly 
by pipetting up and down. 
6. Add 2 mls of the cell mixture to a new well 
7. *Repeat the protocol if you are making additional replicates  
8. Place the plate in the 37°C incubator 
9. After 24 hours, shift the cells to DM 
10. Change the DM every 24 hours 
 
 
 
 
 117 
 
  
 
 
 
 
X. BCKA rescue experiment in BCAT2 siRNA cells 
Reagents: 
1. α-ketoisocaproate (KIC) (Sigma #K0629) 
a. dilute in autoclaved ddH20 to make stock concentration of 25 mg/ml 
b. pass solution through sterile syringe filter 
2. α-ketomethylvalerate (KMV) (Sigma #K7125) 
a. dilute in autoclaved ddH20 to make stock concentration of 25 mg/ml 
b. pass solution through sterile syringe filter 
3. α-ketoisovalerate (KIV) (Sigma #198994) 
a. dilute in autoclaved ddH20 to make stock concentration of 25 mg/ml 
b. pass solution through sterile syringe filter 
 
Procedure: 
1. Perform siRNA transfection in 6-well plates as described in “siRNA transfection protocol” 
2. Make enough plates to have three treatment groups: SCR siRNA, BCAT2 siRNA, BCAT2 
siRNA + BCKAs 
3. 24 hours after transfection add 1-ml GM 
a. After adding GM, add sterile KIC, KIV, and KMV to make the final concentration 
200 µM for each BCKA 
4. After another 24 hours, shift the cells to DM 
a. After adding DM, add sterile KIC, KIV, and KMV to make the final concentration 
200 µM for each BCKA 
5. Change the DM every 24 hours, and add the BCKAs every day as well 
6. Harvest the cells at each day of differentiation with regular lysis buffer 
KD KD KD 
CTR   
KD   
CTR   
 
Rinse, trypsinize, and combine 
cells into a new tube. 
Resuspend the cells in 2mls 
GM/new well. Add 2 mls of 
the cell mix to the new well. 
Thus in KD wells we have 3x as 
many cells and in SCR wells 
we have 1x as many cells. 
